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ABSTRACT 
 
TIMOTHY BENJAMIN SAURER:  Neuroimmune Mechanisms of Opioid-Mediated 
Immunomodulation 
(Under the direction of Donald T. Lysle, Ph.D.) 
 
 
Administration of opioid drugs such as morphine and heroin elicits pronounced 
effects on the immune system, including decreases in natural killer (NK) cell activity and 
lymphocyte proliferative responses.  Despite a wealth of data indicating that opioids induce 
such immune alterations by acting through µ-opioid receptors in the brain, there is little 
known about how opioids interact with neurotransmitter systems to modulate specific 
immune parameters.  The present investigations address how opioid interactions with 
dopamine transmission in the nucleus accumbens translate into peripheral immune 
alterations.  The experiments presented in Chapter 2 revealed that pharmacological blockade 
of dopamine D1 receptors in the nucleus accumbens shell abolished the suppressive effects of 
both morphine and heroin on the ability of splenic NK cells to lyse tumor cell targets.  In 
contrast, selective stimulation of dopamine D1 receptors in the nucleus accumbens shell 
produced reductions in splenic NK cell activity comparable to opioid administration.  
Additionally, antagonism of D1 receptors in the nucleus accumbens shell completely 
prevented heroin’s inhibitory effects on in vivo iNOS expression in spleen, liver, and lung 
tissues.  Chapter 3 showed that these dopamine-dependent immunomodulatory effects are 
mediated peripherally via the sympathetic peptide transmitter NPY.  Administration of a 
selective NPY Y1 receptor antagonist blocked opioid-induced decreases of NK activity and 
 iv
iNOS expression, but did not reverse the suppression of dopamine-independent effects on 
lymphocyte proliferative responses.  Chapter 4 showed that similar dopamine and NPY 
receptor mechanisms underlie the conditioned immunomodulatory effects of opioids.  Rats 
received conditioning sessions during which an injection of morphine was paired with a 
distinctive environment that served as the conditioned stimulus (CS).  Administration of a 
either a D1 antagonist or a Y1 antagonist prior to CS re-exposure fully blocked the 
conditioned suppression of NK cell activity.  Collectively these findings suggest that opioid-
induced increases in dopamine release in the nucleus accumbens shell inhibit splenic NK 
activity and iNOS production by facilitating the NPY release from sympathetic nerves.  
Additionally, the findings suggest that conditioned and unconditioned immunomodulatory 
effects of opioids involve similar receptor mechanisms. 
 v
 
 
 
 
 
TABLE OF CONTENTS 
 
 
 
LIST OF FIGURES………………………………………………………….…………….....ix 
 
LIST OF ABBREVIATIONS……………………………………………………………...…xi 
 
Chapter 
 
I. GENERAL INTRODUCTION…….………………………………………….1 
 
History of Opioids….………………………………………….………………1 
 
Opioids and Health:  Historical Background….………………………………5 
 
Opioid-induced Immunomodulation….……………………………………….6 
 
 Phenomenological Observations………………………………………6 
 
 Peripheral Mechanisms…………………………………………...…...8 
 
Central Mechanisms………………………………………………….10 
 
 Role of Dopamine……………………………………………....……11 
 
 Role of Neuropeptide Y……………………………………………...13 
 
Conditioned Immunomodulation….…………………………………..……..15 
 
Goals of the Dissertation…………………………………………………......17 
 
II. ROLE OF NUCLEUS ACCUMBENS DOPAMINE IN  
OPIOID-INDUCED IMMUNE ALTERATIONS ………………………….19 
 
Introduction…………………………………………………………………..19 
 
Materials and Methods……………………………………………………….22 
 
 Animals………………………………………...…………………….22 
 
 vi
 Drugs……………………………………………...………………….22 
 
 Systemic Dopamine Antagonism…………………………………….23 
  
 C-Fos Immunohistochemistry…………………..……………...…….23 
  
 Surgical and Microinjection Procedures………………………….….24 
 
 Immunotoxin Administration Procedure….………..…..……………26 
 
 Tissue Collection…………………………………………………….27 
 
 Natural Killer Cell Assay…………………………………………….27 
 
 Splenocyte Proliferation Assay……………………...……………….28 
 
 Real-Time RT-PCR…………………………………....…………….29 
 
 Statistics…………………………………………..………………….30 
 
Results……………………………………………………………………..…31 
 
 Effects of Morphine…………………………………………….....…31 
 
  Systemic dopamine receptor antagonism………...………..…31 
 
  Induction of c-Fos expression……………………………..…32 
 
  Nucleus accumbens D1 receptor antagonism…….………..…34 
 
  Intra-accumbens immunotoxin administration………..…..…35 
  
 Effects of Dopamine D1 Agonist Administration………………....…36 
  
 Effects of Heroin…………..………………………………..……..…37 
 
  Heroin dose response analysis…………..…………….......…37 
 
  Effect of D1 receptor antagonism on NK activity……..…..…38 
 
  Effect of D1 receptor antagonism  
on splenocyte proliferation………………………………..…40 
 
Effect of D1 receptor antagonism  
on iNOS expression……………………………………….…41 
 
 vii
Discussion………………………………………………………………...….42 
 
III. NEUROPEPTIDE Y-DEPENDENT MECHANISMS  
IN OPIOID-INDUCED IMMUNOMODULATION….…………………….50 
 
Introduction…………………………………………………………………..50 
 
Materials and Methods…………………………………………………….…53 
 
Animals…………………………………………………...……….…53 
 
 Drugs……………………………………………………………....…53 
 
 Surgical and Drug Administration Procedures...………………….…53 
 
 Tissue Collection………………………………………………….…55 
 
 Natural Killer Cell Assay………………………………………….…56 
 
 Splenocyte Proliferation Assay………...………………………….…56 
 
 Real-Time RT-PCR……………………………………………….…56 
 
 Statistics…………………………………………………….………..56 
 
Results……………………………………………………………………..…57 
 
   NPY Y1 Receptor Antagonism:  Morphine-Induced Effects……...…57 
 
   Exogenous NPY Administration…………………………………..…59 
 
   NPY Y1 Receptor Antagonism: 
Dopamine Agonist-Induced Effects……………………………….…61 
 
NPY Y1 Receptor Antagonism:   
Heroin-Induced Effects……………..……………………………..…62 
 
Discussion……………………………………………………………………63 
 
IV. NEUROIMMUNE MECHANISMS OF OPIOID-MEDIATED 
CONDITIONED IMMUNOMODULATION……………………………….71 
 
Introduction…………………………………………………………………..71 
 
Materials and Methods……………………………………………………….74 
 
 viii
Animals……………………………………………………………....74 
 
 Drugs…………………………………………………………...…….75 
 
 Conditioning Procedures……………………………………………..75 
 
 Surgical and Microinjection Procedures………………………….….77 
 
 Tissue Collection…………………………………………………….78 
 
Natural Killer Cell Assay…………………………………………….79 
 
 Splenocyte Proliferation Assay…………………………………...….79 
 
 Statistics……………………………………………..……………….79 
 
Results……………………………………………………………………..…80 
 
 Systemic D1 Receptor Antagonism…………………………………..80 
 
 Nucleus Accumbens D1 Receptor Antagonism…………………...…82 
 
 NPY Y1 Receptor Antagonism…………………………………....…84 
 
Discussion……………………………………………………………….…...85 
 
V. GENERAL DISCUSSION………………………………………………......90 
 
Experimental Findings..........………………………………………………...90 
 
Potential Mechanisms………………………………………………………..92 
 
Opioid/Dopamine Interactions……………………………………….92 
 
Nucleus Accumbens Efferent Pathways…………………………..…94 
 
NPY Mechanisms………………………………………………...….95 
 
Biological Implications…………………………………………………..…..97 
 
Conclusions…………………………………………………………………102 
 
REFERENCES……………………………………………………………………..104 
 
 ix
LIST OF FIGURES 
 
Figure 
 
2.1. Effect of systemic dopamine receptor antagonists on morphine-induced 
 suppression of splenic NK activity…………………………………..…………32 
 
2.2. Morphine-induced c-Fos expression in the nucleus accumbens………………..33 
 
2.3. Effect of D1 receptor antagonism in the nucleus accumbens shell 
 or core on morphine-induced suppression of NK cell activity…………………35 
 
2.4. Effect of intra-accumbens immunotoxin administration on  
 morphine-induced suppression of NK cell activity…………………………….36 
 
2.5. Effect of nucleus accumbens dopamine D1 receptor stimulation  
 on splenic immune measures……….……………………………...………..….37 
 
2.6. Effects of heroin dose on splenic immune measures………………..………….38 
 
2.7. Effect of D1 receptor antagonism in the nucleus accumbens shell 
  on heroin-induced suppression of NK cell activity……………………….……39 
 
2.8. Effect of D1 receptor antagonism in the nucleus accumbens shell on 
 heroin-induced decreases in splenocyte mitogenic responses………………….41 
 
2.9. Effect of D1 receptor antagonism in the nucleus accumbens shell on  
 heroin-induced reductions of iNOS mRNA expression ……………..…………42 
 
3.1. Effect of NPY Y1 receptor antagonism on morphine-induced 
 suppression of splenic NK activity ………………………………………….…58 
 
3.2. Effect of NPY Y1 receptor antagonism on morphine-induced 
 suppression of splenic lymphocyte proliferation ………………………………59 
 
3.3. Effect of NPY administration on splenocyte immune measures ……………....60 
 
3.4. Effect of NPY Y1 receptor antagonism dopamine D1 agonist-induced 
 suppression of NK cell activity…………………………………………………62 
 
3.5. Effect of NPY Y1 receptor antagonism on heroin-induced alterations 
 of iNOS mRNA expression ……………………………………………………63 
 
4.1. Effect of systemic dopamine D1 receptor antagonism on conditioned 
 suppression of splenic NK cell activity ……………………………………..…80 
 
 x
4.2. Effect of systemic D1 receptor antagonism on conditioned 
 suppression of lymphocyte proliferation……………………………………….82 
 
4.3. Effect of D1 receptor antagonism in the nucleus accumbens shell 
 or core on conditioned suppression of NK cell activity…………...……………83 
 
4.4. Effect of NPY Y1 receptor antagonism on conditioned reductions 
 of NK cell activity………………………………………………………………84 
 
 
 xi
LIST OF ABBREVIATIONS 
 
AIDS  acquired immune deficiency syndrome 
ANOVA analysis of variance 
C  Celsius 
CNS  central nervous system 
Con-A  concanavalin A 
 CS  Conditioned stimulus 
DAT  dopamine transporter 
DNA  Deoxyribonucleic acid 
DPM  disintegrations per minute 
GABA  gamma-aminobutyric acid 
 HPA  hypothalamic-pituitary-adrenal 
i.c.v.  intracerebroventricular 
IL-1  interleukin 1 
iNOS  inducible nitric oxide synthase 
i.v.  intravenous 
LPS  lipopolysaccharide 
mRNA  messenger ribonucleic acid 
NK  natural killer 
NPY  neuropeptide Y 
PAG  periaqueductal gray matter 
PCR  polymerase chain reaction 
 xii
RNA  ribonucleic acid 
RT-PCR reverse transcriptase polymerase chain reaction 
s.c.  subcutaneous 
S.E.  standard error 
SNS  sympathetic nervous system 
 TNF-α  tumor necrosis factor-alpha 
UCS  unconditioned stimulus 
vol  volume 
VTA  ventral tegmental area 
 
 
 
 
 
 
CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
 
 
History of Opioids 
 Opioid drugs have been used in the form of crude opium since prehistoric times, 
making them among the oldest psychoactive drugs known to man (Booth, 1998).  Opium is a 
naturally occurring substance obtained from the sap of the immature seedpod of the opium 
poppy Papaver somniferum.  Because opium use antedates recorded history, it is unknown 
when and where opium’s psychoactive properties were initially discovered.  However, 
historians generally agree that by ca. 3400 B.C., the Sumerians had become familiar with 
opium’s euphoric properties as they referred to the opium poppy as “hul gil,” meaning the 
“joy plant” (Booth, 1998; Scott, 1969).  Thus, the Sumerians, renowned as the world’s first 
civilization and credited with the invention of writing, are also recognized for introducing 
opium to the ancient world (Brownstein, 1993). 
Opium eventually spread from Sumer (the area known as present-day Iraq) to the 
Egyptians, who first documented the drug’s medicinal properties in ancient medical texts.  
The Ebers Papyrus (ca. 1500 B.C.), mentioned opium in some 700 remedies including a 
notable “remedy to prevent excessive crying of children,” which required concocting an 
amalgam of poppy plants and fly excrement (Booth, 1998; Brownstein, 1993).  Therapeutic 
uses of opium were also recognized by the Greek physician Hippocrates (ca. 460-357 B.C.), 
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the father of modern medicine, and later by Galen (ca. 130-201 A.D.) who extolled opium as 
a cure for a number of sundry ailments including headaches, deafness, fever, leprosy, 
jaundice, and melancholy, among others (Scott, 1969).  In addition, ancient Greek writers 
such as Homer and Theophrastus alluded to the use of opium as an epicurean indulgence 
(Booth, 1998).   
Despite the fact that opium was used recreationally in ancient times, there were few 
references to the problem of opium addiction.  The philosopher Diagoros of Melos in the 3rd 
century B.C. may have been the first to recognize the danger of opium addiction when he 
declared that it was better to endure pain than to become bound to opium (Booth, 1998).  
Nonetheless, the social and medical problems associated with opium addiction were not fully 
realized until nearly 1,500 years later in China (Scott, 1969).  The primary reason opium 
addiction became such a problem in China was that rather than eating or drinking opium, as 
was common in Europe and the Middle East, the Chinese popularized the practice of 
smoking opium (Yaroschuk, 2000).  Smoking the drug intensified its euphoric effects by 
increasing potency and accelerating opium’s entry to the brain.  Consequently, opium 
smoking carried a much greater risk of addiction.  China’s opium problem became so severe 
that it led to the first law against opium smoking, declared in 1729 by the Chinese emperor 
(Scott, 1969). 
 In spite of the problems in China, opium was entirely legal and readily available in 
various preparations throughout Western societies for much of the 19th century (Maisto et al., 
2004).  Opium’s popularity was fueled by authors of the time-period who praised the drug’s 
effects.  Most notably, British poet Thomas DeQuincey’s book Confessions of an English 
Opium Eater undoubtedly inspired many readers to experiment with opium’s so-called “keys 
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of Paradise” (Maisto et al., 2004).  Not surprisingly, as opium’s popularity became more 
widespread in Europe, so to did concern about the grave consequences of opium dependence. 
In the early 1800s, the German chemist F.W. Setürner isolated the major active 
component of opium and called it morphine after Morpheus, the Greek god of dreams 
(Huxtable and Schwarz, 2001).  Morphine was discovered to be about 10 times more potent 
than opium, and with the invention of the hypodermic syringe by Alexander Wood in 1856, 
morphine dependence quickly became a major problem (Levinthal, 2005).  Wood’s invention 
permitted a means of injecting morphine to provide rapid and potent pain-relief for severe 
wounds.  As an unfortunate consequence, many soldiers during the American Civil War 
became dependent on the drug—so many in fact, that morphine dependence became known 
as “soldier’s disease” (Levinthal, 2005). 
In 1898, the German pharmaceutical company Bayer introduced a new compound 
called heroin, which was created through a chemical modification to morphine (Booth, 
1998).  Bayer initially marketed heroin as a “safe” cough suppressant, and although it was 
approximately three times as potent as morphine, it was purported to be free from morphine’s 
abuse liability (Levinthal, 2005).  This was the first of many such claims for new drugs based 
on dubious evidence and overzealous interpretation1 (Eddy, 1957).  Consequently, doctors 
began to prescribe heroin as a treatment for morphine addiction.  By 1910, it became 
apparent that heroin was even more addictive than morphine, and by 1913, heroin had 
replaced morphine as the leading cause of narcotic-related hospital admissions in the United 
States (Yaroschuk, 2000). 
                                                 
1 Surprisingly, many physicians of the time-period also heralded cocaine as a cure for morphine addiction.  Not 
surprisingly, this caused a dramatic increase in the number of morphine addicts who were also addicted to 
cocaine (Karch, 2005). 
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Rising concerns about the danger of opioid dependence in the early 1900s led to a 
series of major changes in public policy in the United States.  The 1914 Harrison Narcotics 
Tax Act limited the use of opioids for medical treatment by requiring a physician’s 
prescription and effectively transformed morphine addiction from a disease into a criminal 
offense virtually overnight (Yaroschuk, 2000).  Increasingly strict regulations were enacted 
shortly thereafter, and heroin was totally banned and permanently removed from medical 
usage in 1924 (Maisto et al., 2004).  By 1970, the escalation of major changes in drug policy 
culminated with sweeping legislation that consolidated existing drug laws under the 
Controlled Substances Act and established the Drug Enforcement Agency as the federal drug 
law enforcement authority (Yaroschuk, 2000).  This marked the beginning of the so-called 
‘war on drugs.’ 
 Despite more stringent laws and severe penalties for illicit drug use, in 2005, it was 
estimated that a staggering 19.7 million Americans had used illicit drugs within the past 
month (SAMHSA, 2006).  Roughly 108,000 Americans aged 12 or older abused heroin for 
the first time in 2005, with approximately 164,572 heroin-related emergency department 
visits reported in the same year (SAMHSA, 2007).  In addition to the major problems 
surrounding the use of illicit opioids, abuse of opioid-based prescription drugs has escalated 
in recent years, as evidenced by reports that nearly 12 million Americans had used painkillers 
recreationally in 2005 (SAMHSA, 2006).  In fact, of all U.S. emergency room visits in 2005 
involving (nonmedical) use of legal pharmaceuticals and supplements, opioid-based 
painkillers accounted for one-third (196,225), a 24% increase from 2004 (SAMHSA, 2007).  
There is little question that opioid abuse remains a significant problem in the United States. 
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Opioids and Health:  Historical Background 
Infectious disease was not widely associated with opioid addiction until the early 
1900s (Friedman et al., 2003).  Ironically, for most of the 19th century, opium use was 
actually believed to prolong life (Risdahl et al., 1998).  The association between opium use 
and disease did not emerge into public consciousness until the 1870s.  Literary author Alonzo 
Calkins noted in that opium addiction was “plagued with disease” in his 1871 publication of 
Opium and the Opium Appetite (Risdahl et al., 1998).  Only four years later, Thomas 
Whipham published a case study of an opium addict that had developed pleuropneumonia 
and argued that addiction accelerated progression of the disease and increased the likeliness 
of death (Risdahl et al., 1998).  By the turn of the century, it was realized that morphine 
addiction carried with it a palpable risk for numerous infectious complications including 
tetanus, pneumonia, and nephritis among others (Crothers, 1902; Norman, 1876; Osburne, 
1892).   
The list of infectious diseases associated with opioid use grew progressively longer 
throughout the 20th century—a reality that mirrored the increasingly common problem of 
heroin addiction.  The post-World War II heroin epidemic in the United States spawned a 
number of clinical studies of heroin addicts, including a landmark study by Hussey and Katz 
(1950) that described numerous infectious complications such as skin abscesses, septicemia, 
endocarditis, and malaria.  Reports of high infection rates among opiate addicts continued to 
proliferate with the ‘drug culture explosion’ of the 1960s to include an impressive list of 
bacterial, viral, and fungal infections including skin sepsis, bacterial and fungal endocarditis, 
septicemia, viral hepatitis, bacterial bronchopneumonia, malaria, and tetanus (Cherubin, 
1971; Hussey and Katz, 1950; Louria et al., 1967; Luttgens, 1949). 
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As infectious diseases became viewed as common complications of opioid addiction, 
conventional wisdom held that the high incidence of infections among addicts was primarily 
due to increased exposure to pathogens resulting from the use of contaminated needles or 
tainted drugs.2  In addition, researchers hypothesized that lifestyle practices may also represent 
a risk factor.  For example, opioid addicts commonly engage in insalubrious behavioral 
practices that result in malnutrition, stress, sleep deprivation, and/or alcohol abuse.  Certainly, 
there are many factors that contribute to the high incidence of infections among addicts.  
However, the impact of opioids per se on the immune system was not widely considered—or 
at least did not generate a great deal of research interest—until  the emergence of the 
HIV/AIDS epidemic, when it was revealed that heroin use was a major risk factor for HIV-
infection (Ginzburg, 1984; Quagliarello, 1982).  This observation drew considerable 
attention to the possibility that drugs themselves may influence disease resistance, and thus a 
new directive emerged to identify potential biological mechanisms by which opioids may 
modify immunological processes. 
 
Opioid-Induced Immunomodulation 
Phenomenological Observations 
There is compelling evidence that opioids disrupt immune function in humans.  
Clinical studies report that heroin users display a variety of immunological abnormalities 
compared to non-users, including lower numbers of circulating lymphocytes, decreased NK 
cell activity, and reduced antibody-dependent cellular cytotoxicity (Brown et al., 1974; 
                                                 
2The notion that opioid drugs per se are innocuous persists to this day, as evidenced in the most recent edition of 
the popular college-level textbook Biopsychology.  In a chapter on drug addiction, the author states, “…the health 
hazards of chronic (opioid) exposure are surprisingly minor.  The main risks are constipation, pupil constriction, 
menstrual irregularity, and reduced libido.  Many opiate addicts have taken pure heroin or morphine for years with 
no serious ill effects.” (Pinel, 2006). 
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Donahoe et al., 1986; Govitrapong et al., 1998; Nair et al., 1986).  These studies were among 
the first to propose that the high incidence of infectious disease among opioid addicts is 
related to impaired immune function.  Interestingly, the association between increased 
infection risk and opioid use is not restricted to drug abusing populations.  Recent clinical 
reports indicate that higher doses of opioid analgesics are associated with greater incidence 
of infectious complications among burn victims and cardiac patients (El Solh et al., 2006; 
Schwacha et al., 2006).  Furthermore, controlled studies indicate that acute morphine 
exposure produces immunosuppressive effects in healthy, non-drug using individuals 
(Tubaro et al., 1985; Yeager et al., 1995).  Thus, the use of opioids—whether for therapeutic 
or recreational purposes—appears to increase infection susceptibility independently of 
addiction-related risk factors such as intravenous drug use. 
Although clinical observations and a limited number of controlled human studies 
support the hypothesis that opioid-induced immune alterations alter disease resistance, the 
immunomodulatory properties of opioids have been predominantly ascertained from animal 
models.  Interestingly, the immunomodulatory properties of opioids appear to be conserved 
across mammalian species, as opioid-induced immune alterations have been demonstrated in 
human, monkey, pig, rabbit, rat, and mouse (e.g., Carr et al., 1994a; Carr and France, 1993; 
Olin et al., 2007; Shavit et al., 1987; Tubaro et al., 1983; Yeager et al., 1995).  A major 
advantage of animal models is that they permit the experimenter to control for confounding 
variables inherent to clinical studies that complicate the determination of cause-effect 
relationships (e.g., differences in age, nutrition, medical history, drug history, etc.).  In 
addition, because human studies are largely limited to the analysis of peripheral blood, the 
use of animals permits a more comprehensive evaluation of opioid-induced changes in 
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immune status through examination of other tissues such as the spleen, lymph nodes, lung, 
and liver.  Morphine is the most commonly used opioid in animal studies since it is 
considered the prototype µ-opioid receptor agonist and because the biological effects of 
heroin are chiefly attributed to its major active metabolite (morphine).  Studies have shown 
that morphine administration suppresses a number of immune parameters, including NK cell 
activity (Bayer et al., 1990a; Shavit et al., 1986), lymphocyte proliferation (Bayer et al., 
1990b; Lysle et al., 1993), antibody production (Lefkowitz and Chiang, 1975; Lockwood et 
al., 1994), and interferon production (Hung et al., 1973).  Moreover, morphine has been 
shown to alter host resistance to various infectious and neoplastic diseases (Lewis et al., 
1983; Tubaro et al., 1983).  Importantly, morphine’s immunomodulatory effects are dose-
dependent and can be prevented by the opioid receptor antagonist naltrexone, indicating that 
morphine’s effects on immunity are due to the drug’s pharmacological activity (Lysle et al., 
1993). 
 
Peripheral Mechanisms 
 Although the immunomodulatory effects of opioids have been extensively documented, 
the mechanisms by which opioids exert these effects are not entirely understood.  Because 
opioid receptors are expressed by numerous cell types throughout the body, a major research 
focus has been to determine the site of action of opioids.  One direction of this work tests 
whether opioids alter immune status by acting directly on cells of the immune system via cell-
surface opioid receptors.  Wybran and colleagues (1979) provided some of the first evidence 
for the presence of opioid receptors on human peripheral blood T-lymphocytes by showing that 
naloxone reverses the suppression of active T-cell rosette formation by morphine.  Subsequent 
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investigations implicated the involvement of µ-opioid receptors in particular (Chuang et al., 
1995; Mehrishi and Mills, 1983; Sedqi et al., 1995), although others have reported the 
existence of additional opioid receptor subtypes as well as naloxone-insensitive morphine 
binding sites (Joseph and Bidlack, 1994; Lawrence et al., 1995; Madden et al., 1987; Roy et al., 
1992). 
 The opioid receptors found on immunocytes appear to be functional, since in vitro 
exposure to morphine produces concentration-dependent and opioid antagonist-reversible 
alterations in several assays of immune status.  For example, morphine suppresses Con A-
stimulated interferon-γ production (Peterson et al., 1987) and enhances the growth of HIV-1  
in human peripheral blood mononuclear cell cultures (Peterson et al., 1990). Furthermore, 
addition of morphine to murine peritoneal macrophage cultures suppresses phagocytic 
activities (Casellas et al., 1991; Rojavin et al., 1993; Szabo et al., 1993).  In contrast, other 
studies report no direct effect of morphine or effects only at very high concentrations (Fuchs 
and Pruett, 1993; Pruett et al., 1992; Thomas et al., 1995; Yeager et al., 1992).  For example, 
Bayer et al. (1992) showed in rats that only high concentrations of morphine suppress 
lymphocyte proliferation when added directly to mitogen-stimulated splenocyte and blood 
cultures, but these effects are not antagonized by naltrexone.  Thus, while there is evidence to 
support that morphine directly influences the activity of immune cells, these effects are 
complex and may be specific to certain immune measures.  Taken together, these findings 
indicate that immune cells express functional opioid receptors and provide one pathway 
through which opioids such as morphine modulate the immune system. 
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Central Mechanisms 
Another site of action for opioids is through the regulatory actions of the central 
nervous system (CNS) on the immune system.  Substantial evidence supports the existence of a 
complex, bi-directional link between the CNS and the immune system (e.g., Felten et al., 
1985), and there is experimental evidence that morphine's immunomodulatory effects involve 
central opioid receptors.  An initial study by Shavit et al. (1986) found that systemic 
administration of morphine, but not N-methylmorphine (a form of morphine which does not 
readily penetrate the blood-brain barrier), produces a naltrexone-reversible suppression of 
splenic natural killer cell activity in the rat.  That same study showed that 
intracerebroventricular (i.c.v.) administration of morphine dose-dependently suppresses splenic 
natural killer cell activity, and prior administration of naltrexone blocks the effect of i.c.v. 
morphine.  Along similar lines, microinjections of morphine directly into the periaqueductal 
gray region of the rat brain produce a highly significant, naltrexone-sensitive suppression in 
splenic natural killer cell activity (Weber and Pert, 1989).  Bayer and colleagues showed that 
microinjection of morphine into the anterior hypothalamus inhibits blood lymphocyte 
proliferation to mitogen (Hernandez et al., 1993).  In addition, studies from our laboratory have 
shown that a single i.c.v. microinjection of morphine dose-dependently alters lymphocyte 
proliferation to T- and B-cell mitogens and natural-killer cell cytotoxicity in the spleen (Lysle 
et al., 1996).  Our studies also showed that i.c.v. administration of N-methylnaltrexone dose-
dependently antagonizes the immunomodulatory effects of systemic morphine administration, 
whereas systemic administration of N-methylnaltrexone (at doses that do not act centrally) are 
ineffective in blocking morphine's effects (Fecho et al., 1996a).  Thus, there is an 
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overwhelming amount of evidence implicating a role of the central nervous system in opioid-
induced immune alterations. 
 
Role of Dopamine 
Despite a wealth of data indicating that morphine modulates immune status by acting 
at opioid receptors in the brain, little is known about how the opioid system interacts with 
other neurotransmitter systems to modulate specific immune parameters.  Our laboratory has 
recently provided evidence that the regulation of central dopaminergic pathways is an 
important mechanism of morphine-induced immune alterations.  Morphine exerts a 
stimulatory effect on midbrain dopamine neurons that project to forebrain structures such as 
the nucleus accumbens and dorsal striatum, resulting in increased cell firing and elevated 
extracellular dopamine levels.  Because several of the behavioral effects of morphine are 
dependent on dopamine transmission, we initially hypothesized that dopamine may also play 
an important role in morphine-induced immunomodulation. 
We began testing the hypothesis that dopamine mediates morphine-induced 
immunosuppression by examining the effect of the dopamine D2-like receptor agonist 7-OH-
DPAT on acute morphine treatment in rats (Saurer et al., 2004).  Five dopamine receptor 
subtypes have been identified (D1-D5), and these are divided into D1-like family (D1, D5) and 
the D2-like family (D2, D3, D4) based on biochemical, pharmacological, and physiological 
properties.  It is generally considered that there are opposing effects of D1 and D2 receptor 
activation on cAMP-dependent signaling, with D1-like receptors coupling to stimulatory Gs-
proteins, and D2-like receptors acting through inhibitory Gi/o proteins (Missale et al., 1998; 
Stoof and Kebabian, 1981).  Because of the complexity of dopamine receptor pharmacology, 
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we selected 7-OH-DPAT for use in our initial study because it had been shown to antagonize 
dopamine signaling at the behavioral, cellular, and molecular level, possible due to activity at 
dopamine autoreceptors.  For instance, 7-OH-DPAT inhibits stimulated endogenous 
dopamine release (Patel et al., 1995) and attenuates a diverse set of morphine-induced 
behaviors associated with increased dopamine signaling (Cook et al., 1999; Rodriguez et al., 
1995; Suzuki et al., 1995).  Moreover, 7-OH-DPAT functionally antagonizes dopamine 
signaling at the molecular level as evidenced by data showing that 7-OH-DPAT abolished 
morphine-induced expression of c-Fos protein (a marker of neuronal activation) in several 
dopamine terminal regions (unpublished data).  Results from our study showed that 
administration of 7-OH-DPAT into the lateral ventricle dose-dependently attenuated 
morphine-induced reductions of splenic NK cell activity at several-fold lower doses than 
were effective following systemic administration (Saurer et al., 2004).  These findings 
provided the first direct evidence that central dopaminergic mechanisms are involved in 
morphine-induced immunomodulation. 
The mesocorticolimbic system is perhaps the most widely studied dopaminergic 
system with respect to its interactions with opioids because it is an integral component of the 
so-called ‘reward circuitry’ of the brain.  Dopamine neurons in this system arise from the 
ventral tegmental area of the midbrain and project to the prefrontal cortex and to limbic areas 
such as the nucleus accumbens and the amygdala.  In particular, the stimulatory influence of 
morphine on dopamine signaling in the nucleus accumbens has been extensively documented 
both neurochemically and electrophysiologically.  Importantly, dopamine receptors in the 
nucleus accumbens modulate several of morphine’s behavioral effects including 
reinforcement (Shippenberg et al., 1993) and analgesia (Altier and Stewart, 1998).    The 
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latter finding is of particular significance because neural pathways subserving morphine’s 
effect on immune functions have been suggested largely based on studies indicating that the 
immunoregulatory and analgesic effects of morphine involve similar neural structures.  For 
example, microinjection of morphine into the PAG produces both analgesia (Yaksh et al., 
1976) and suppression of NK activity (Weber and Pert, 1989), and the onset of morphine’s 
immunologic and analgesic effects follows a similar time course (Nelson et al., 1997).  More 
importantly however, is that the nucleus accumbens has been also been shown to regulate 
immune functions, as lesions (Deleplanque et al., 1994) or pharmacological manipulation 
(Nistico et al., 1994) of mesoaccumbens dopamine neurons results in altered immune 
responses.  Overall, there is a substantial amount of indirect evidence to suggest that opioids 
alter components of host defense by modulating the dopaminergic input to the nucleus 
accumbens. 
 
Role of Neuropeptide Y 
The efferent mechanisms whereby centrally acting opioids modulate peripheral 
immunity involves both the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic 
nervous system (SNS).  The production of glucocorticoids from the adrenal glands is thought 
to play an important role in the effects of chronic morphine exposure on immune status 
(Freier and Fuchs, 1994), but this does not appear to mediate the effects of acute morphine 
administration (Bayer et al., 1990b).  The SNS on the other hand, mediates many of the 
immunomodulatory effects of acute morphine exposure.  For example, the suppressive 
effects of acute morphine administration on mitogenic responses of T cells and B cells are 
prevented by pretreatment with β-adrenoceptor antagonists (Fecho et al., 1993a).  However, 
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morphine-induced reductions in splenic NK cell activity are not blocked by either peripheral 
adrenoceptor antagonists or adrenalectomy, suggesting than neither the HPA axis nor 
sympathetic catecholamines are involved (Carr et al., 1994b; Fecho et al., 1993a; Fecho et 
al., 1996b). 
Little is known regarding the peripheral mechanism whereby morphine inhibits 
splenic NK activity.  Immunocytochemical studies have suggested that NPY may be an 
important modulator of splenocyte functions given the presence of NPY in postganglionic 
sympathetic fibers innervating the spleen (Romano et al., 1991).  NPY is released upon 
sympathetic activation and induces a host of immunomodulatory effects.  Notably, there have 
been several investigations of the relationship between NPY and NK activity.  For example, 
circulating NPY levels, but not catecholamines, were inversely correlated with NK activity in 
Alzheimer’s caregivers, suggesting that NPY regulates NK activity under physiological 
conditions in vivo (Irwin et al., 1991).  Further support for this hypothesis was provided by 
the demonstration that NPY produces a direct and dose-dependent inhibition of NK activity 
in vitro (Nair et al., 1993).  Although the mechanism of the effect of NPY on NK cells is not 
fully understood, the discovery of functional NPY Y1 receptors on rat splenic lymphocytes 
offers the possibility that NPY may interact directly with its cognate receptors on NK cells to 
suppress cytolytic activity (Bedoui et al., 2002; Petitto et al., 1994).  One of the key 
objectives of the experiments described in Chapter 3 is to examine the role of the 
sympathetic peptide transmitter NPY in opioid-induced reductions in NK cell activity. 
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Conditioned Immunomodulation 
Studies of Pavlovian conditioning of immunity have provided some of the most 
convincing evidence for reciprocal communication between the nervous system and the 
immune system.  The basic conditioning paradigm involves the temporal pairing of a neutral 
conditioned stimulus (CS), such as a novel taste, odor, or context, with a stimulus that 
actively evokes an immunomodulatory response, termed the unconditioned stimulus (UCS).  
Following the CS-UCS pairing, re-exposure to the CS alone alters immune functioning in a 
manner which mimics the normal or unconditioned effect of the UCS.  Ader and Cohen 
(1975) provided one of the earliest demonstrations of conditioned immunomodulation by 
showing that a gustatory stimulus which has been paired with the immunosuppressive drug 
cyclophosphamide can acquire immunosuppressive properties in mice. Subsequent 
investigations have demonstrated that many immune measures are modifiable by 
conditioning including both humoral and cell-mediated immune responses (for review, see 
Ader and Cohen, 1993).  In addition to animal studies, conditioned immune alterations have 
been demonstrated in humans as well (Exton et al., 2000b; Goebel et al., 2002).  
Furthermore, evidence from a number of studies which have investigated the effects of 
conditioned immune alterations on disease processes suggests that conditioning phenomena 
are clinically relevant.  For example, conditioned effects on the immune system have been 
shown to significantly influence morbidity and mortality in animal models of lupus (Ader 
and Cohen, 1982), rheumatoid arthritis (Klosterhalfen and Klosterhalfen, 1983; Lysle et al., 
1992b), allergic dermatitis (Exton et al., 2000a), organ transplantation (Exton et al., 1998), 
and neoplastic disease (Gorczynski et al., 1985).  Interestingly, it is possible to condition 
increases or decreases in immune measures such as NK cell activity, with the direction of the 
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conditioned effect mirroring that of the unconditioned effect (Ghanta et al., 1985; O'Reilly 
and Exon, 1986). 
While there is undoubtedly a myriad of receptors and signaling molecules involved 
the mediation of complex processes such as Pavlovian conditioning of immunity, there has 
been considerable interest in the role of the endogenous opioid system.  A number of studies 
using different conditioning models have shown that many of the behavioral and 
physiological effects of opioid drugs can be conditioned, suggesting that the opioid system is 
particularly integral to several conditioning phenomena.  For instance, the involvement of 
opioid receptors has been established in studies of conditioned taste aversion (Leblanc and 
Cappell, 1975), conditioned analgesia (Miller et al., 1990), and conditioned hyperthermia 
(Lal et al., 1976).  Notably, opioid receptors have also been shown to mediate a number of 
conditioned immunomodulatory effects.  Much of the impetus for investigating the role of 
endogenous opioids in conditioned immunomodulation was derived from early studies 
showing that the opioid antagonist naltrexone blocked reductions in NK activity produced by 
exposure to inescapable electric shock in rats (Cunnick et al., 1988; Shavit et al., 1984). 
Further studies demonstrated that these stressor-induced, opioid-mediated immune alterations 
could be conditioned to the environmental context (the CS) associated with the stressful or 
aversive stimulus.  For example, the presentation of a CS which has previously been paired 
with aversive electric shock produces naltrexone-reversible reductions in NK cell activity and 
lymphocyte mitogenic responses (Lysle et al., 1992a).  These conditioned immune alterations 
were subsequently shown to be mediated specifically by µ-opioid receptors in the central 
nervous system, providing direct evidence for the involvement of the central opioid system in 
conditioned immunomodulation (Perez and Lysle, 1997). 
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Similar to the effects of stress, morphine’s pharmacological effects on immune status 
can also be conditioned to environmental stimuli.  For example, when rats are re-exposed to a 
distinctive environment in which they have previously received morphine, immunological 
alterations occur that are similar to those produced by the drug alone, including decreased 
mitogen responsiveness of blood and splenic lymphocytes, reduced interleukin-2 production, 
and decreased NK cell activity in the spleen (Coussons et al., 1992; Coussons-Read et al., 
1994a; Coussons-Read et al., 1994b).  These conditioned effects are specifically associated 
with re-exposure to the CS, as extensive control procedures have shown that the immune 
alterations are not related to extraneous procedural variables (Coussons et al., 1992).  
Because opioid drugs typically produce immunosuppression, conditioned stimuli paired with 
opioid administration acquire immunosuppressive properties.  Thus, an important implication is 
that any detrimental health consequences of opioid use may also be conditioned to 
environmental stimuli and not solely due to pharmacological properties of the drug.  
 
Goals of the Dissertation 
This dissertation addresses a void in current knowledge regarding the neuroimmune 
mechanisms of opioid-mediated immunomodulation.  The present studies examine effects of 
both heroin and morphine on several immune parameters to provide a general assessment of 
the mechanisms involved in opioid-induced immune alterations.  Given the paramount 
importance of NK cells for surveillance and resistance to infections and cancers, NK cell 
activity is an important parameter of immune function to consider when investigating the 
effects of opioids.  Furthermore, by using a model of Gram-negative bacterial infection to 
examine the effects of heroin on iNOS production, these studies will provide valuable 
 18
information regarding the mechanisms whereby opioids alter resistance to infectious 
diseases.    Chapter 2 describes the role of dopamine receptors in the nucleus accumbens as 
a central mediator of opioid-induced immune alterations.  Chapter 3 examines the 
contributions of the sympathetic transmitter NPY as a potential peripheral mediator of the 
dopamine-dependent immunomodulatory effects of opioids.  Finally, Chapter 4 evaluates 
whether conditioned environmental stimuli modulate immune status by acting through 
similar receptor pathways as exogenous opioids.  Collectively, these projects will provide 
valuable insights to the field of neuroimmunology by elucidating novel receptor mechanisms 
of opioid-mediated immunomodulation.  Furthermore, given that the capacity to increase 
dopamine levels in the nucleus accumbens is shared by other drugs of abuse, these studies 
may have important mechanistic implications for how other classes of abused drugs alter 
immune status. 
 
 
 
 
 
CHAPTER 2 
ROLE OF NUCLEUS ACCUMBENS DOPAMINE IN OPIOID-INDUCED IMMUNE 
ALTERATIONS 
 
 
 
 
Introduction 
Opioids suppress a number of immune parameters indirectly through interactions with 
the central nervous system.  Such neural modulation of the immune system is a precisely 
regulated phenomenon, as stimulation of opioid receptors in different areas of the brain 
selectively modifies distinct immunological parameters.  To date, opioid receptors in the 
periaqueductal gray matter and the anterior hypothalamus have been identified as sites that 
mediate the immunomodulatory effects of morphine.  Beyond these initial investigations 
however, there has been little progress toward the elucidation of neural mechanisms that 
underlie the immunological effects of opioids.  Because peripheral immune responses are 
regulated at all levels of the neuraxis, it is likely that opioids influence immunity through 
interactions with numerous neural structures.  Surprisingly however, there is virtually 
nothing known about how the stimulation of opioid receptors interacts with other brain 
regions to modulate immune functions.  
Recently, our laboratory has shown that morphine’s effects on the immune system 
involve central dopamine systems (Saurer et al., 2004).  Midbrain dopamine neurons, which 
innervate basal ganglia and limbic structures of the forebrain, play an important role in the 
regulation of peripheral immune responses.  Lesion studies in rats indicate that the 
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destruction of nigrostriatal or mesolimbic dopamine neurons impairs both cellular and 
humoral immune measures as evidenced by changes in NK cell activity and altered immune 
responses to foreign antigen (Deleplanque et al., 1994; Devoino et al., 1997).  Furthermore, it 
has been reported that the stimulation of D1 receptors in the nucleus accumbens produces 
immunosuppressive effects as evidenced by decreased splenic lymphocyte proliferative 
responses (Nistico et al., 1994).  Given that morphine administration patently stimulates 
dopamine release in the nucleus accumbens, we hypothesized that dopamine receptors in the 
nucleus accumbens may comprise a critical neural substrate of opioid-mediated 
immunomodulation. 
  The studies described in the current chapter begin to characterize the dopaminergic 
mechanisms involved in opioid-induced immunomodulation by first examining the effects of 
opioids on splenic NK cell activity.  NK cells are a distinct population of lymphocytes that 
constitute the immune system’s first line of defense against a variety of infections and 
cancers.  It is because of their unique ability to spontaneously (without prior sensitization) 
and selectively (without damaging normal cells) kill tumor cells that they are called “natural 
killer” cells (Kiessling et al., 1975).  The ability of NK cells to lyse target cells is an 
important effector mechanism in host defense as it plays an indispensable role in resistance to 
viral (Biron et al., 1999; Whiteside and Herberman, 1994) and metastatic diseases 
(Herberman and Ortaldo, 1981; Whiteside and Herberman, 1995).  Most importantly with 
respect to the current study, data from our laboratory and that of many others clearly 
demonstrate that ex vivo NK cell cytolytic responses are extraordinarily sensitive to the 
effects of in vivo opioid administration (Lysle et al., 1993; Nelson et al., 1997; Shavit et al., 
1986; Weber and Pert, 1989). Therefore, a key objective of this chapter is to elucidate a 
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central dopaminergic mechanism through which opioids may act to suppress this crucial 
immune function parameter—NK cell activity. 
To test the hypothesis that dopamine receptors in the nucleus accumbens mediate the 
effects of morphine on NK cell activity, the current studies first examine the contributions of 
dopamine receptor subtypes using the D1 receptor antagonist SCH-23390 and the D2 
antagonist raclopride.  Immunostaining for c-Fos protein was utilized to identify areas of 
neuronal activation within the nucleus accumbens (i.e., core vs. shell) following morphine 
injection, and subsequent investigations examined whether morphine’s NK suppressive effect 
is contingent upon the activation of D1 receptors in the core or shell subdivisions of the 
nucleus accumbens.  Furthermore, using the selective D1 receptor agonist SKF-38393, the 
present study evaluates the effect of direct D1 receptor stimulation on immune status. 
To determine whether the mechanisms of morphine’s effects generalize to the more 
the commonly abused opioid heroin, the present study also examines the role of the nucleus 
accumbens in heroin-induced alterations of NK activity and splenic lymphocyte proliferation.  
Importantly, heroin’s effect on the in vivo expression of inducible nitric oxide synthase 
(iNOS) was also assessed to determine whether dopaminergic mechanisms underlie opioid 
effects on in vivo immune measures.  The iNOS enzyme plays a critical role in disease 
resistance because it is responsible for the production of nitric oxide in response to infectious 
challenges.  The generation of nitric oxide by cells of the immune system has potent anti-
microbial and anti-tumor effects and may also be involved in regulating the immune response 
per se (Green et al., 1990; Green and Nacy, 1993; Hibbs et al., 1987; James and Glaven, 1989; 
Karupiah et al., 1993; Rossi et al., 1999; Vincendeau et al., 1992).  Since iNOS is not 
expressed under normal physiological conditions, but rather must be induced, enzyme levels 
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are commonly used as a marker of nitric oxide production3.  In the present study, we stimulate 
iNOS production with lipopolysaccharide (LPS), the major immunogenic component expressed 
on the surface of Gram-negative bacteria.  Thus, LPS injection provides a useful model to 
examine the in vivo effects of heroin on the immune response to Gram-negative infection.   
Collectively, the studies presented in this chapter provide an extensive evaluation of the role 
of dopamine D1 receptors in the nucleus accumbens shell in the effects of opioids on several 
critical parameters of immune function. 
 
Materials and Methods 
Animals 
 Adult male Lewis rats weighing approximately 200-250 grams were purchased from 
Charles River Laboratories (Raleigh, NC).  Upon arrival, animals were individually housed 
and maintained on a reverse 12-hr light/dark cycle.  Animals were habituated to handling and 
the colony room environment for two weeks prior to any experimental manipulation.  Food 
and water were available ad libitum throughout the experiment. 
 
Drugs 
Morphine sulfate (NIDA, Bethesda, MD), diacetylmorphine sulfate (heroin; NIDA), 
R(+)-SCH-23390 hydrochloride (Sigma-Aldrich, St. Louis, MO), S(-)-raclopride (+)-tartrate 
salt (Sigma), and R(+)-SKF-38393 hydrochloride (Sigma) were dissolved in sterile 0.9% 
saline.  For all experiments, morphine was administered s.c. at a dose of 15 mg/kg in a 1.0 
ml/kg volume.  This dose was selected based on previous studies from our laboratory 
showing that the effects of morphine are dose-dependent and that the effects were blocked by 
                                                 
3 Nitric oxide is a volatile gaseous molecule that is difficult to quantify directly. 
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naltrexone, indicating the involvement of opioid receptors (Lysle et al., 1993).  Heroin was 
administered s.c. at doses of 1, 3, 5, or 10 mg/kg  in a 1.0 ml/kg volume.  Dose-effect 
analyses indicated that 3 mg/kg heroin induced a maximal effect so this dose was used for all 
subsequent studies.  Anti-DAT-saporin (Advanced Targeting Systems, San Diego, CA) was 
diluted in sterile PBS to a final concentration of 0.5 µg/µl. 
 
Systemic Dopamine Antagonism 
The effect of D1 or D2 dopamine receptor antagonism was determined using SCH-
23390 or raclopride respectively.  In the first experiment rats were assigned to one of six 
groups (n = 4 per group) in which they received the D1 receptor antagonist SCH-23390 (0, 
0.1, or 1.0 mg/kg, s.c.) 30 minutes prior to saline or morphine.  This experiment was 
replicated using the same design, and the data was combined for analysis (n = 7 – 8 per 
group).  In the second experiment rats were assigned to one of eight groups (n = 3) in which 
they received an injection of raclopride (0, 0.1, 1.0, or 3.0 mg/kg, s.c.) 30 minutes prior to 
injection of morphine or saline. 
 
C-Fos Immunohistochemistry 
Given the functional distinctions between the core and shell components of the 
nucleus accumbens, we assessed the pattern of neuronal activation in the core and shell to 
determine whether morphine differentially activated these areas in the male Lewis rat at a 
dose of 15 mg/kg.  Animals were assigned to two groups (n = 3 per group) in which they 
received a s.c. injection of morphine or saline in a 1 ml/kg volume.  Two hours later, animals 
were deeply anesthetized with ketamine/xylazine and transcardially perfused with cold saline 
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followed by a 4% paraformaldehyde solution.  Brains were removed and post-fixed for two 
days.  Immunohistochemistry was performed on free-floating 50 µm cryostat-sliced coronal 
sections using the avidin-biotin-peroxidase (ABC) method (Vectastain Elite Kit, Vector 
Laboratories, CA) with DAB detection.  The primary antibody used was goat anti-c-Fos IgG 
(Santa-Cruz Biotechnology, CA, sc-52, diluted 1:20,000).  c-Fos labeled cells were counted 
using the bright field method on an Olympus BX51 microscope interfaced with ImagePro 
Plus software (Media Cybernetics, Silver Spring, MD).  A standard rectangle (size 
determined by region being analyzed) was placed over the area of interest and the number of 
labeled cells was counted automatically by the software.  Counts were performed bilaterally 
and averaged over 4 consecutive sections for each animal. 
 
Surgical and Microinjection Procedures 
For all microinjection experiments, animals were implanted with bilateral guide 
cannulae (Plastics One, Roanoke, VA) one week prior to drug administration.  Stereotaxic 
surgeries were performed under anesthesia induced with a 0.2 ml intramuscular injection of a 
1:1 (vol/vol) mixture of ketamine (100 mg/ml) and xylazine (20 mg/ml).  On the test day, 
animals receiving microinjections into the accumbens shell were assigned to one of six 
groups (n = 3 – 4) in which they received SCH-23390 (0, 0.015, or 0.15 µg/side) 30 minutes 
prior to morphine or saline administration.  This experiment was replicated twice using the 
same design, and the data was combined for analysis (n = 7 – 12 per group).  SCH-23390 
was administered in a 0.5 µl volume per side via a 33-gauge injector that protruded 2 mm 
beyond the tip of the guide cannula (AP +1.7, ML ±1.0, DV –7.4).  Coordinates are 
expressed as millimeters from bregma (Paxinos and Watson, 1986). 
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A separate experiment using the same design was performed to examine the effect of 
SCH-23390 administration into the nucleus accumbens core.  Animals were assigned to one 
of six groups (n = 4) in which they received SCH-23390 (0, 0.015, or 0.15 µg/side) 30 
minutes prior to morphine or saline administration.  SCH-23390 was administered in a 0.5 µl 
volume per side via a 28-gauge injector that protruded 2 mm beyond the tip of the guide 
cannula (AP +1.7, ML ±1.9, DV –6.8). 
The effects of D1 antagonism on heroin-induced immune alterations were examined 
in a subsequent series of experiments.  To determine the effects on NK activity and 
lymphocyte proliferation, SCH-23390 (0, 0.015, or 0.15 µg/side) was administered 30 
minutes prior to heroin or saline (n = 5 – 6 per group).  Microinjections were delivered in a 
0.5 µl volume per side via a 33-gauge injector that protruded 2 mm beyond the tip of the 
guide cannula (AP +1.7, ML ±0.8, DV –7.4).  The same experimental procedures were used 
to evaluate the effects of D1 antagonism on iNOS production.  In this experiment, animals 
were assigned to one of six groups (n = 3 – 4) in which they received SCH-23390 (0, 0.015, 
or 0.15 µg/side) 30 minutes prior to heroin or saline in combination with an injection of LPS 
(1000 µg/kg, s.c.).  This experiment was replicated twice using the same design, and the data 
was combined for analysis (n = 6 – 7 per group). 
For all experiments, drug was infused over a 30 second period using a microsyringe 
pump (Harvard Apparatus, Holliston, MA) and the injector was left in place for one minute 
to allow diffusion of the drug away from the injection site.  Following drug treatment and 
sacrifice, Alcian Blue dye was injected via the cannula and brains were removed and post-
fixed in 4% paraformaldehyde for two days.  Brains were transferred to a 30% sucrose 
solution for cryoprotection, frozen, and stored at -80˚C for subsequent analysis.  Accurate 
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cannulae placements were verified by examination of 50 µm thionin-stained tissue sections 
under a light microscope.  Only animals with placements within the targeted region were 
included in the analysis.     
The effect of direct pharmacological activation of nucleus accumbens D1 receptors on 
NK activity was investigated by implanting rats with bilateral cannulae into the nucleus 
accumbens shell as described above.  Animals were assigned to one of four groups (n = 4 per 
group) in which they received bilateral microinjections of the D1 agonist SKF-38393 (0, .05, 
.5, or 5.0 µg/side).  SKF-38393 was administered in a 0.5 µl volume per side according to the 
procedure described previously.  Animals were sacrificed one hour later to assess splenic NK 
activity and splenocyte proliferative responses.  Cannulae placements were verified as 
described above. 
 
Immunotoxin Administration Procedure 
The immunotoxin anti-DAT-saporin is a highly selective dopaminergic cytotoxin that 
utilizes a monoclonal antibody to target cells expressing the dopamine transporter (DAT) 
(Wiley et al., 2003).  Under stereotaxic surgery, anesthetized animals received bilateral 
injections of anti-DAT-saporin (0.5 µg/side) into the nucleus accumbens shell (AP+1.7, 
ML±1.0, DV-7.4).    Immunotoxin injections were performed using a microsyringe pump 
(Harvard Apparatus) that delivered 1.0 µl/side of the toxin over a 60s interval.  Bilateral 
injections were performed simultaneously via a bilateral 33 gauge injector (Plastics One), 
and the injectors remained in place for an additional minute to allow diffusion of the toxin 
into the parenchyma.  Sham lesions were performed by injecting an equivalent volume of 
phosphate buffered saline vehicle.  Two weeks following toxin administration, animals 
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received a subcutaneous injection of morphine (15 mg/kg) or saline.  One hour later, animals 
were sacrificed and splenocytes were used to determine NK activity. 
 
Tissue Collection 
 One hour following morphine, heroin, or saline injections, rats were sacrificed by 
cervical dislocation.  This time point was selected based on previous data from our laboratory 
indicating a maximal suppression of the measured immune parameters 1 h following 
morphine administration.  The spleen was removed and placed in 7 ml of RPMI-1640 tissue 
culture media supplemented with 10 mM HEPES, 2 mM glutamine, and 50 µg/ml gentamicin 
(hereafter referred to as supplemented RPMI; GIBCO, Grand Island, NY).  Each spleen was 
prepared as a single-cell suspension by gently pressing the tissue between two sterile, frosted 
microscope slides in supplemented RPMI enriched with 10% fetal bovine serum (hereafter 
referred to as complete RPMI; GIBCO).  Splenic leukocytes were counted using a Hemavet 
850 cell analyzer (CDC Technologies Inc., Oxford, CT), and cell suspensions were adjusted 
to 5 × 106 leukocytes/ml by diluting with complete RPMI.  Prior work by our laboratory has 
utilized flow cytometry to demonstrate that acute morphine treatment does not alter the total 
number of leukocytes or the relative number of each major leukocyte subpopulation 
(including NK cells) in the spleen (Fecho and Lysle, 1999). 
 
Natural Killer Cell Assay 
 Splenic NK cell activity was assessed using a standard chromium release assay.  
Adjusted splenocyte suspensions were co-incubated with the murine T-cell lymphoma, YAC-
1. The YAC-1 target cells were labeled by incubation for 70 min with 200 µCi of sodium 
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chromate-51 [51Cr].  YAC-1 cells were then washed three times with complete RPMI to 
remove exogenous [51Cr].  Splenic leukocytes were used as effectors and were plated in 
triplicate at 10, 5, 2.5, and 1.25 × 105 cells/well of a 96 well plate.  Labeled targets were 
diluted and plated at 1 × 104 cells/well to give effector/target (E:T) ratios of 100:1, 50:1, 25:1 
and 12.5:1.  Following a 5 h incubation at 37°C in a humidified CO2 incubator, the amount of 
[51Cr] released into the supernatant was determined using an LKB gamma counter (model 
1272 CliniGamma).  Percent specific lysis at all E:T ratios were used to calculate lytic units 
(Pross and Maroun, 1984).  Results are reported as the number of lytic units per 107 effector 
cells, where a lytic unit is defined as the number of splenic leukocytes necessary to lyse 20% 
of the target cells. 
 
Splenocyte Proliferation Assay 
Mitogen stimulation assays were completed using adjusted splenocyte suspensions.  
Splenic T- and B-lymphocyte proliferation was induced with the mitogens Con-A and LPS 
(Sigma-Aldrich), respectively.  One hundred microliters of the adjusted cell suspensions 
were pipetted in triplicate into microtiter plate wells containing final concentrations of 0, 0.5, 
and 5.0 µg/ml Con-A and 0.5 and 5.0 µg/ml LPS.  Splenocyte cultures were then incubated 
for 48 hours at 37°C in a humidified CO2 incubator.  Each culture well was pulsed with 1 µCi 
of [3H] thymidine during the last 5 hours of the incubation period. Cultures were then 
harvested onto glass fiber filter paper using a Tomtec automatic 96-well cell harvester.  The 
amount of [3H]-thymidine incorporated into the DNA of proliferating cells was measured 
using a liquid scintillation counter (Wallac, Model 1205) and is expressed as the mean of the 
triplicate disintegrations per minute (DPM) for the samples from each rat. 
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Real-Time RT-PCR 
To determine iNOS expression, real-time reverse transcriptase polymerase chain 
reaction (RT-PCR) was performed. Total RNA was extracted from a section of each spleen, 
liver, and lung using TRI-Reagent (Molecular Research Center, Cincinnati, OH), a 
modification of the original method described by Chomczynski and Sacchi (1987). RNA was 
quantified spectrophotometrically (GeneQuant II, Pharmacia-Biotech, Piscataway, NJ, USA). 
For the RT-PCR, reverse transcription is performed using Oligo(dT)18 primer and Moloney 
Murine leukemia virus-reverse transcriptase following the protocol of the advantage RT-for-
PCR kit from Clontech (Palo Alto, CA, USA). PCR amplifications were performed using the 
Fast Start™ DNA Master SYBR Green I real-time PCR kit (Roche) and the LightCycler 
instrument (Roche). A master mix containing all reaction components was prepared for all 
reactions, with each reaction using a 20-ml mix placed in glass capillary tubes specifically 
designed for use in the LightCycler system. The PCR primer set for iNOS, 5′-
CCCTTCCGAAGTTTCTGGCAGCAGC-3′ and 5′-GGGTGTCAGAGTCTTGTGCCTT-
TGG-3′, was synthesized by the Nucleic Acids Core Facility (Lineberger Cancer Center, 
UNC-Chapel Hill). Copy numbers were generated from an external standard curve. 
Amplifications were carried out for 40 cycles, and curves showing fluorescence at each cycle 
were determined by the computer software (Roche). Samples were pre-incubated for 10 min 
at 95°C to activate the Fast-Start Taq DNA polymerase.  The cycle temperatures were 95, 60, 
and 72°C for the denaturing, annealing, and extending, respectively. The cycle times were 
15, 5, and 25 s for the denaturing, annealing, and extending, respectively. Fluorescence level 
was determined at the end of the extending phase for each cycle of PCR. The analysis of the 
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fluorescence level in standards and samples over the course of 40 cycles was used to derive 
the number of copies of the target molecule in each sample. Additionally, assessments of 
housekeeping gene expression, cyclophilin, were made to assure comparable quality of RNA 
among samples. The sequence of the cyclophilin primers was 5′-CCAAGACTGAGTGGCT-
3′ and 5′-AGATTACAGGGTATTGCG-3′. The data are expressed as the ratio of iNOS 
mRNA copies (per 10 ng cDNA) to cyclophilin copy number based on the standard curve 
using the LightCycler software (Roche).  Furthermore, to confirm the nature of amplification 
product, a melt curve analysis was conducted after the final PCR cycle. This analysis 
involved denaturing the products by slowly heating them to 95°C, during which fluorescence 
is continuously measured. 
 
Statistics 
Data analysis for all dopamine antagonist administration studies was performed using 
a two-way analysis of variance (ANOVA), with experimental replication entered into the 
model as a covariate to control for inter-assay variability in baseline NK activity when 
appropriate.  For the two-way analysis, the first factor was antagonist dosage and the second 
factor was the type of subsequent injection (morphine/heroin or saline).  Data from the 
immunotoxin study was also analyzed using a two-way ANOVA to assess the impact of 
immunotoxin exposure on morphine’s NK suppressive effect.  Analysis of c-Fos expression 
was performed using independent samples t-tests.  For the SKF-38393 administration and 
heroin-dose effect studies, one-way ANOVA was utilized.  For all analyses, polynomial 
contrasts and planned contrasts were performed in accordance with a priori hypotheses.  
Planned contrasts in each analysis consisted of pairwise comparisons of means between 
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opioid treatment groups and saline treatment groups at each level of the factor “antagonist 
dosage.”  All analyses were performed with the level of significance set at p < 0.05. 
 
Results 
Effects of Morphine 
Systemic dopamine receptor antagonism 
The first study examined the effect of subcutaneous administration of the D1 receptor 
antagonist SCH-23390 or the D2 receptor antagonist raclopride on morphine-induced 
decreases in splenic NK activity.  Figure 2.1 (panel A) shows the results of experiments 
examining the effect of SCH-23390.  Planned comparisons between the saline/saline and 
saline/morphine treatment groups showed that morphine produced a significant decrease in 
NK cell activity [F(1, 36) = 23.72; p < .0001].  Analysis of variance revealed a significant 
interaction between morphine treatment and SCH-23390 dose [F(2, 36) = 11.02; p < .001].  
Polynomial contrasts showed a significant linear component to the interaction indicating that 
the suppressive effect of morphine was attenuated by SCH-23390 administration in a dose-
dependent manner [F(1, 36) = 21.26; p < .0001].  Furthermore, planned comparisons 
revealed that the high dose of SCH-23390 completely blocked the suppressive effect of 
morphine, as the groups that received 1.0 mg/kg of SCH-23390 prior to morphine or saline 
administration were not significantly different [F(1, 36) = 2.72; p > .05]. 
The effect of subcutaneous raclopride administration on morphine-induced 
suppression of NK activity is shown in Figure 2.1 (panel B).  Analysis of variance yielded a 
significant main effect of morphine treatment [F(1, 16) = 73.57; p < .0001], indicating that 
morphine suppressed NK activity.  There was not a significant effect of raclopride dose [F(3, 
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16) = 0.47; p > .05], nor was there a significant interaction effect [F(3, 16) = 0.46; p > .05].  
Moreover, planned comparisons indicated that morphine reduced NK activity at each dose of 
raclopride tested (ps < .001). 
 
 
 
Figure 2.1  Effect of systemic dopamine receptor antagonism on morphine-induced 
suppression of splenic NK activity.  A, Subcutaneous administration of the D1 antagonist 
SCH-23390 dose-dependently attenuated the effect of morphine.  B, Treatment with the D2 
antagonist raclopride did not alter the effect of morphine on NK activity.  Data are expressed 
as lytic units (mean ± S.E.).  *p < .05; **p < .001 compared with appropriate saline-treated 
control group that received the same dose of dopamine antagonist. 
 
 
Induction of c-Fos expression 
Photomicrographs of c-Fos protein expression in the nucleus accumbens in the core 
and shell following morphine or saline treatment are displayed in Figure 2.2 (A-D).  
Compared to saline treatment, morphine did not increase the number of c-Fos positive cells 
in the core subregion of the nucleus accumbens [t(4) = 0.58; p > .05] (Figure 2.2, panel E).  
In the shell of the nucleus accumbens however, morphine induced a significant increase in 
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the number of c-Fos labeled cells compared to saline treatment [t(4) = 4.61, p < .01] (panel 
F).  These results show that the same dose of morphine used to elicit immunosuppression 
produces an activation of the nucleus accumbens shell, but not the core, in the male Lewis 
rat.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2  Expression of c-Fos protein in the nucleus accumbens following injection of 
saline (A, B) or 15 mg/kg morphine (C, D).  Representative photomicrographs of the nucleus 
accumbens core (A, C) and shell (B, D) are shown.  Data in E and F are expressed as c-Fos 
labeled cells (mean ± S.E.) counted bilaterally and averaged over four consecutive 50 µm 
sections for each animal.  Morphine administration produced a significant increase in c-Fos 
positive cells in the nucleus accumbens shell but had no effect in the core.  Magnification, 
10×.  *p < 0.01 compared to saline-treated group. 
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Nucleus Accumbens D1 receptor antagonism 
Because the D2 antagonist raclopride—a compound which readily crosses the blood-
brain barrier (Hall et al., 1988)—did not attenuate the effect of morphine on NK activity, 
only the D1 antagonist SCH-23390 was administered in the microinjection studies.  Figure 
2.3 (panel A) shows the effects of SCH-23390 microinjections into the nucleus accumbens 
shell on morphine-induced alterations in NK activity.  Planned comparisons demonstrated 
that morphine significantly reduced NK cell activity compared to saline treatment among 
animals that received microinjections of saline [F(1, 47) = 18.49; p < .001].  Analysis of 
variance revealed a significant interaction between morphine treatment and SCH-23390 dose 
[F(2, 47) = 5.65; p < .01] and polynomial contrasts showed a significant linear component to 
the interaction indicating that the suppressive effect of morphine was attenuated by SCH-
23390 administration in a dose-dependent manner [F(1, 47) = 11.26; p < .01].  Furthermore, 
planned comparisons revealed that the high dose of SCH-23390 completely blocked the 
suppressive effect of morphine, as the groups that received 0.15 µg/side SCH-23390 prior to 
morphine or saline administration were not significantly different [F(1, 47) = 0.19; p > .05].   
These findings show that D1 antagonist administration into the nucleus accumbens shell 
prevents the suppression of NK activity by morphine. 
The effect of SCH-23390 administration into the nucleus accumbens core is shown in 
Figure 2.3 (panel B).  Analysis of variance revealed a significant main effect of morphine 
[F(1, 18) = 52.23; p < .0001].  There was no effect of SCH-23390 dose [F(2, 18) = 2.31; p > 
.05] , nor was there a significant interaction between SCH-23390 dose and morphine 
treatment [F(2, 18) = 2.32; p > .05].  Planned comparisons further indicated that morphine 
decreased NK activity at each dose of SCH-23390 tested (ps < .01).  These findings suggest 
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that D1 receptors located in the nucleus accumbens core do not mediate the effect of 
morphine on splenic NK activity and provide additional support for the specificity of 
microinjections in the shell. 
 
Figure 2.3  Effect of D1 receptor antagonism in the nucleus accumbens shell (A) or core (B) 
on morphine-induced suppression of NK cell activity.  Rats received bilateral microinjections 
of saline or SCH-23390 into the nucleus accumbens prior to a subcutaneous injection of 
morphine.  A, Administration of SCH-23390 into the shell dose-dependently attenuated the 
effect of morphine on NK activity.  B, SCH-23390 microinjections into the core did not alter 
the effect of morphine.  Data are expressed as lytic units (mean ± S.E.).  *p < .05; **p < .001 
compared to the saline-treated control group that received an equivalent dose of SCH-23390. 
 
 
Intra-accumbens immunotoxin administration 
An additional study was conducted to determine whether dopaminergic immunotoxin 
administration into the nucleus accumbens shell would disrupt the effect of morphine on NK 
activity.  Figure 2.4 displays the results of the anti-DAT-saporin immunotoxin experiment.  
Planned comparisons demonstrated that morphine significantly reduced NK cell activity 
compared to saline treatment in the sham-lesion group [F(1, 12) = 17.31; p < .01).  Analysis 
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of variance revealed a significant interaction between morphine and immunotoxin treatment 
[F(1, 12) = 10.15; p < .01].  In addition, planned comparisons show that NK activity in the 
morphine treated group was not different from the saline group among animals that received 
immunotoxin infusions [F(1, 12) = 0.12; p > .05], indicating that the effect of morphine was 
abolished by anti-DAT-saporin exposure. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4  Effect of intra-accumbens immunotoxin administration on morphine-induced 
suppression of NK cell activity.  Rats received bilateral microinjections of vehicle (sham-
lesions) or the dopaminergic toxin anti-DAT-saporin (immunotoxic lesions) into the nucleus 
accumbens shell.  The effect of morphine on NK activity was assessed two weeks later.  
Immunotoxin administration prevented the suppressive effect of morphine on NK activity.  
Data are expressed as lytic units (mean ± S.E.).  *p < .05 compared with sham-lesioned, 
saline-treated group. 
 
 
 
Effects of Dopamine D1 Agonist Administration 
A subsequent experiment examined whether the activation of D1 receptors in the 
absence of morphine is sufficient to produce immune alterations.  The results of the NK 
assay displayed in Figure 2.5 show that administration of SKF-38393 into the nucleus 
accumbens shell induced significant reductions in splenic NK activity [F(3, 12) = 4.17; p < 
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.05].  Polynomial contrasts showed a highly significant linear component to the SKF-38393 
treatment [F(1, 12) = 10.09; p < .01], indicating that the suppressive effect of SKF-38393 on 
NK cytolytic activity increased in a dose-dependent manner.  Conversely, SKF-38393 did not 
alter T or B cell proliferative responses to Con-A [F(3, 12) = 0.20; p > .05] or LPS [F(3, 12) 
= 0.22; p > .05], respectively. 
 
 
Figure 2.5  Effect of nucleus accumbens dopamine D1 receptor stimulation on splenic 
immune measures.  Rats received bilateral microinjections of saline or SKF-38393 into the 
nucleus accumbens shell one hour prior to sacrifice.  SKF-38393 treatment produced a 
suppression of NK activity at the two highest doses tested.  Con-A and LPS stimulated 
proliferative responses were not altered at any dose tested.  Data are expressed as lytic units 
(mean ± S.E.).  *p < .05 compared with saline-treated group. 
 
 
 
Effects of Heroin 
Heroin dose-response analysis 
To expand the generality of the previous findings with morphine, the present study 
also investigated the role of the nucleus accumbens in mediating heroin-induced immune 
alterations.  The optimal dose of heroin for producing immune alterations was first 
established by conducting a dose-response analysis.  The results of this experiment are 
displayed in Figure 2.6.  Analysis of variance yielded a significant main effect of dose on NK 
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cell activity, indicating that heroin reduced NK activity [F(4, 15) = 16.22; p < .0001].  
Furthermore, planned comparisons showed that heroin significantly decreased cytolytic 
activity at every dose (ps < .001).  Figure 2.6 also displays the effects of heroin of splenocyte 
proliferative responses to Con-A and LPS.  There was a significant main effect of heroin on 
proliferation induced by Con-A [F(4, 14) = 36.51; p > .0001].  Planned comparisons further 
showed that heroin significantly decreased mitogenic responses to Con-A at each dose 
examined (ps < .05).  Analysis of variance also revealed a significant main effect of heroin 
on LPS-induced proliferation [F(4, 14) = 33.89; p < .0001].  The effect of heroin on LPS-
induced proliferation was evident at each dose tested as determined by planned comparisons 
with the saline control group (ps < .05). 
 
 
Figure 2.6  Effects of heroin dose on splenic immune measures.  Subcutaneous heroin 
administration significantly suppressed NK activity at each dose.  Heroin also significantly 
decreased splenocyte mitogenic responses to Con-A and LPS at each dose examined, with 
more pronounced effects at doses of 3 mg/kg or higher.  Data from the cytotoxicity assay 
data are expressed as lytic units (mean ± S.E.).  Data from proliferation assays are expressed 
as disintegrations per minute (mean ± S.E.).  *p < .05; **p < .001 compared with appropriate 
saline-treated control group. 
 
 
Effect of D1 receptor antagonism on NK activity 
The effect of SCH-23390 administration into the nucleus accumbens shell on heroin-
induced decreases in NK activity is shown in Figure 2.7.    Analysis of variance revealed 
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significant main effects of heroin treatment [F(1, 27) = 18.15; p < .001] and SCH-23390 dose 
[F(2, 27) = 6.02; p < .01].  Planned comparisons demonstrated that heroin significantly 
reduced NK cell activity compared to saline treatment in animals that received saline 
microinjections [F(1, 27) = 16.48; p < .001].  Planned comparisons also revealed that both 
doses of SCH-23390 attenuated the effect of heroin, since there was no significant difference 
between heroin and saline treated groups in animals that received SCH-23390 at a dose of 
0.015 µg/side [F(1, 27) = 3.76; p > .05], or 0.15 µg/side [F(1, 27) = 1.90; p > .05].  
Importantly, among groups that received subcutaneous saline injections, SCH-23390 did not 
significantly alter NK activity compared to saline microinjections at either dose tested (ps > 
.05).  These findings show that D1 antagonist administration into the nucleus accumbens shell 
prevents the suppression of NK activity induced by heroin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7  Effect of D1 receptor antagonism in the nucleus accumbens shell on heroin-
induced suppression of NK cell activity.  Rats received bilateral microinjections of saline or 
SCH-23390 into the nucleus accumbens prior to a subcutaneous injection of heroin.  Both 
doses of SCH-23390 attenuated the effect of heroin on NK activity.  Data are expressed as 
lytic units (mean ± S.E.).  **p < .001 compared to the saline-treated control group that 
received an equivalent dose of SCH-23390. 
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Effect of D1 receptor antagonism on splenocyte proliferation 
Figure 2.8 (left panel) shows the effect of SCH-23390 administration into the nucleus 
accumbens shell on heroin-induced reductions in proliferative responses to Con-A.  The 
analysis yielded a significant main effect of heroin treatment [F(1,27) = 27.00; p < .0001],  
but there was not a significant effect of SCH-23390 [F(2, 27) = 0.33; p > .05].  Moreover, 
there was not a significant interaction between heroin and SCH-23390 treatment [F(2, 27) = 
0.01; p > .05].  Planned comparisons further indicated that heroin decreased Con-A induced 
proliferation at each dose of SCH-23390 tested (ps < 0.01).   
The effect of SCH-23390 administration on heroin-induced decreases mitogenic 
responses to LPS is shown in the right panel of Figure 2.8.  Analysis of variance revealed a 
significant main effect of heroin [F(1, 27) = 37.62; p < .0001].  There was no effect of SCH-
23390 treatment [F(2, 27) = 0.44; p > .05], nor was there a significant interaction between 
SCH-23390 dose and heroin treatment [F(2, 27) = 0.02; p > .05].  Planned comparisons 
indicated that heroin’s suppressive effect on LPS-induced proliferation was not blocked by 
SCH-23390 at any dose, as the heroin group was significantly decreased relative to the 
appropriate saline control group that received the same dose of SCH-23390 (ps < .01).  These 
findings suggest that D1 receptors located in the nucleus accumbens shell do not mediate the 
effect of heroin on splenocyte proliferative responses. 
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Figure 2.8  Effect of D1 receptor antagonism in the nucleus accumbens shell on heroin-
induced decreases in splenocyte mitogenic responses.  Rats received bilateral microinjections 
of SCH-23390 into the nucleus accumbens prior to a subcutaneous injection of saline or 
heroin.  SCH-23390 did not alter the effect of heroin on splenocyte proliferative responses to 
Con-A or LPS stimulation.  Data are expressed as lytic units (mean ± S.E.).  *p < .01 
compared to the saline group that received the same dose of SCH-23390. 
 
 
Effect of D1 receptor antagonism on iNOS expression 
A final study was performed to examine whether D1 receptors in the nucleus 
accumbens shell also play a role in heroin’s effects on the production of iNOS in vivo.  LPS-
induced expression of iNOS mRNA in spleen, liver, and lung tissues is shown in figure 2.9.  
Planned comparisons demonstrated that, among animals that received saline microinjections, 
heroin significantly reduced iNOS levels compared to saline in the spleen [F(1, 33) = 6.02; p 
< .05]; liver [F(1, 33) = 14.07; p < .001]; and lung [F(1, 33) = 12.11; p < .01].  Analysis of 
variance revealed a significant interaction between SCH-23390 dosage and heroin treatment 
in the spleen [F(2, 33) = 4.50; p < .05]; liver [F(2, 33) = 9.74; p < .001], and lung [F(2,33) = 
7.91; p < .01], indicating that SCH-23390 altered the suppressive effect of heroin in all 
tissues.  Importantly, planned comparisons revealed that heroin and saline treated groups 
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which received 0.15 µg/side SCH-23390 were not significantly different with respect to 
iNOS expression in the spleen [F(1, 33) = 0.23; p > .05]; liver [F(1, 33) = 3.96; p > .05]; or 
lung [F(1, 33) = 1.37; p > .05]. These results indicate that the high dose of SCH-23390 
abolished heroin’s effect on iNOS expression in all tissues. 
 
 
 
Figure 2.9  Effect of D1 receptor antagonism in the nucleus accumbens shell on heroin-
induced reductions of iNOS mRNA expression.  Rats received microinjections of SCH-
23390 into the nucleus accumbens prior to subcutaneous injections of saline or heroin in 
conjunction with LPS administration.  SCH-23390 microinjections prevented the suppressive 
effect of heroin on iNOS expression in the spleen, liver, and lung.  Data are expressed as the 
ratio of iNOS mRNA expression to expression of the housekeeping gene cyclophilin (mean ± 
S.E.).  *p < .05; **p < .001 compared to the saline group that received an equivalent dose of 
SCH-23390. 
 
 
Discussion 
The findings presented in the current chapter demonstrate that nucleus accumbens 
dopamine plays an essential role in the effects of morphine and heroin on several immune 
parameters.  Specifically, the results show that the activation of dopamine D1 receptors in the 
nucleus accumbens shell is necessary to produce opioid-induced reductions of splenic NK 
cell activity and in vivo iNOS expression in spleen, liver, and lung tissues.  Collectively, 
SCH-23390 (µg/side)
iN
O
S
/C
yc
lo
ph
ili
n 
m
R
N
A
 x
 1
00
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0 0.015 0.15
Spleen iNOS
*
SCH-23390 (µg/side)
0.0
0.4
0.8
1.2
1.6
2.0
2.4
0 0.015 0.15
Liver iNOS
**
SCH-23390 (µg/side)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
0 0.015 0.15
Lung iNOS
*
Saline Heroin (3 mg/kg)
 43
these findings characterize a novel central mechanism whereby opioids modulate critical 
immune parameters.   
The present data show that systemic administration of the dopamine D1 receptor 
antagonist SCH-23390 blocked the effect of morphine on splenic NK activity, while the D2 
antagonist raclopride had no effect.  These findings suggest that morphine-induced increases 
in D1 receptor activation may have detrimental effects on the immune system, since the 
ability of NK cells to lyse target cells is an important effector mechanism in host defense that 
correlates highly (73% concordance) with altered host resistance in laboratory animals 
(Luster et al., 1993).  Because NK cells are important for diverse aspects of host defense 
including anti-tumor and antiviral responses, the production of antipathogenic cytokines and 
chemokines, and the modulation of other immune effector functions (Biron et al., 1999; 
French and Yokoyama, 2003; Seaman, 2000; Trinchieri, 1989), opioid-induced decreases in 
NK cytolytic activity may have significant consequences on disease resistance.  To determine 
whether central dopamine D1 receptors mediated the effect of morphine, we examined the 
role of D1 receptors within the nucleus accumbens specifically.  The stimulatory influence of 
morphine on dopamine transmission within the nucleus accumbens has been extensively 
documented, and several studies have provided evidence that peripheral immune responses 
are regulated by mesoaccumbens dopamine neurons (Deleplanque et al., 1994; Devoino et 
al., 1997; Nistico et al., 1994). 
The nucleus accumbens is a heterogeneous structure with two primary divisions, the 
shell and core, that have been distinguished based on anatomical, connectional, and 
functional properties.  To determine whether morphine differentially activates the core or 
shell when administered at a dose that produces immunosuppression, we examined the 
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expression of c-Fos protein as a marker of neuronal activation.  The results indicate that 
morphine selectively induces c-Fos expression in the nucleus accumbens shell.  These 
findings are consistent with other reports that have found preferential c-Fos induction in the 
shell using various doses of morphine in other rat strains (Barrot et al., 1999; Grabus et al., 
2004; Singh et al., 2004).  Taken together with evidence that morphine preferentially 
increases extracellular dopamine in the shell of the nucleus accumbens (Pontieri et al., 1995), 
the analysis of c-Fos expression suggests that the dopamine receptors mediating morphine’s 
effect in the present study are located in the shell subregion.  Therefore, we initially targeted 
the nucleus accumbens shell for SCH-23390 microinjections and found that blockade of D1 
receptors in the shell prevents morphine-induced reductions of splenic NK activity.  
However, because the shell is a narrow region situated directly medial to the core, it is 
possible that injections of antagonist into the shell will diffuse into the core.  To control for 
the possibility of drug diffusion, we also administered SCH-23390 into the core, but the core 
microinjections had no effect on the ability of morphine to suppress splenic NK activity.   
Collectively, these findings indicate that the activation of D1 receptors within the nucleus 
accumbens shell is necessary to elicit morphine-induced reductions of splenic NK activity. 
Additional evidence for the role of the nucleus accumbens in opioid-induced immune 
alterations is provided by data showing that intra-accumbens administration of anti-DAT-
saporin prevents morphine’s suppressive effect on NK activity.  The anti-DAT-saporin 
conjugate is a highly selective dopaminergic immunotoxin that utilizes a monoclonal 
antibody to target cells expressing the dopamine transporter (DAT).  Once the conjugate 
becomes internalized, the saporin toxin moiety is released, leading to ribosome inactivation, 
inhibition of protein synthesis, and eventually cell death.  Full lesion development and 
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complete cellular dissolution are observed after two weeks (Wiley and Kline IV, 2000).  Our 
data show that morphine administration did not suppress splenic NK activity in rats that 
received intra-accumbens shell injections of anti-DAT-saporin (0.5 µg/µl) two weeks earlier.  
It is also important to note that anti-DAT-saporin administration did not alter the baseline 
immune response in saline treated animals, suggesting that immunotoxin exposure does not 
produce non-specific effects on NK cell cytotoxicity.  The dosage of immunotoxin used in 
the current study was selected based on reports that doses up to 8 µg produced no observable 
cellular damage when administered intracerebroventricularly, whereas doses as low as 0.28 
µg produced selective dopamine cell loss when administered directly into the striatal 
parenchyma (Wiley et al., 2003).  Taken together with results from the SCH-23390 
microinjections, these data provide convincing evidence for the role of the nucleus 
accumbens in morphine-induced immunosuppression.  
Another important finding in the present study is that stimulation of accumbens D1 
receptors with SKF-38393 significantly reduces NK cytolytic responses.  Thus, the data 
suggest that not only is D1 activation necessary for morphine-induced reductions in splenic 
NK cell activity, but that direct D1 activation in the nucleus accumbens shell is sufficient to 
suppress NK activity.  This finding is of particular importance given that a common property 
of virtually every abused drug is the ability to increase dopaminergic transmission in the 
nucleus accumbens.  Hence, one might hypothesize that in addition to morphine, other drugs 
of abuse should depress NK cytolytic responses.  Indeed, suppressed splenic NK activity has 
been reported following in vivo administration of heroin (Fecho et al., 2000), amphetamine 
(Nunez-Iglesias et al., 1996), and cocaine (Pacifici et al., 2003).  Though the extent to which 
a nucleus accumbens D1 receptor-mediated mechanism contributed to the observed NK 
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suppression in these studies is unknown, the notion that such diverse pharmacological agents 
may act through a common central mechanism to suppress host immunity is an intriguing 
hypothesis. 
While the immunomodulatory properties of morphine are well known, the effects of 
heroin on immune status have not been extensively investigated.  The paucity of controlled 
studies of heroin’s effects may be partly due to the fact that heroin (diacetylmorphine) is 
readily metabolized to morphine in the body.  Thus, it is frequently assumed that the 
biological effects of heroin and morphine are the same. However, though heroin and 
morphine do produce many similar effects, they also differ in a number of important 
pharmacological properties.  For instance, heroin penetrates the nervous system more rapidly 
than morphine and produces different subjective psychological effects.  Furthermore, several 
studies have indicated that heroin is capable of producing analgesic effects through different 
receptor pathways than morphine  (Bolger et al., 1988; Harrigan and Downs, 1978; Lange et 
al., 1980; Scott and Orr, 1969; Switzman et al., 1981; Tasker and Nakatsu, 1984; Umans and 
Inturrisi, 1981; van Ree et al., 1978).  The heroin molecule per se does not possess intrinsic 
activity at opioid receptors that could account for such discrepancies, but in contrast to 
morphine, heroin is metabolized to 6-monoacetylmorphine, which has a pharmacological 
profile distinct from morphine.  Thus, because metabolites of heroin may engage different 
receptor populations than morphine, it is possible that heroin acts through different neural 
mechanisms to produce immunomodulation.  Therefore, in order to generalize our findings 
with morphine to the more commonly abused opioid heroin, we also investigated whether 
dopamine receptors mediate the effects of heroin. 
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The present findings are the first to show that heroin-induced immune alterations 
involve the activation of nucleus accumbens D1 receptors.  Specifically intra-accumbens D1 
antagonist administration abolished the suppressive effect of heroin on NK activity.  
Interestingly SCH-23390 administration did not attenuate heroin’s suppressive effects on T 
and B cell proliferative responses to mitogen stimulation.  These results are consistent with 
the data showing that stimulation of accumbens D1 receptors with SKF-38393 does not alter 
splenocyte mitogenic responses.  One intriguing aspect of these findings is that nucleus 
accumbens dopamine receptors appear to be selectively involved in a subset of opioid-
induced immune alterations.  That is to say, the effects of opioids on certain immune 
responses seem to be “dopamine-dependent” (e.g., NK cell activity) whereas other responses 
are not (e.g., lymphocyte proliferative responses). 
The current findings also provide evidence that heroin-induced reductions of iNOS 
expression in spleen, lung, and liver tissues are dopamine-dependent effects. The generation 
of large amounts of nitric oxide by cells of the immune system, particularly the macrophage, is 
imperative for host resistance to potentially infectious microbes including bacteria, viruses, and 
parasites (Green et al., 1990; Green and Nacy, 1993; James and Glaven, 1989; Rossi et al., 
1999; Vincendeau et al., 1992).  Our data further substantiate the critical involvement of 
nucleus accumbens dopamine by demonstrating that accumbens D1 receptors mediate the 
effects of heroin on the in vivo immune response to LPS, the major immunogenic component 
expressed on the surface of Gram-negative bacteria.  The injection of LPS is a generally 
accepted model of sepsis, a systemic infection resulting from the proliferation of bacteria in the 
blood (usually due to a failure of immunological defenses) that often leads to multiple organ 
failure and results in death.  The fact that SCH-23390 microinjections prevented the 
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suppression of iNOS in several key organs indicates that the heroin-induced increase of 
nucleus accumbens dopamine has widespread effects on immune system in vivo.  
Furthermore, an important implication of these findings is that the dopamine response to 
heroin may be directly involved in the increased susceptibility to bacterial complications 
among heroin addicts as the result of impaired nitric oxide production.   
An important issue for future studies will be to investigate the efferent mechanisms 
through which increased D1 receptor activation in the nucleus accumbens translates into 
altered peripheral immune responses.  The two major pathways through which the brain 
modulates peripheral immune responses are the HPA axis the sympathetic nervous system.  
The efferent mechanisms that mediate the effect of acute opioid treatment on NK activity and 
iNOS production specifically have not been elucidated to date, but the involvement of the 
HPA axis seems improbable since opioid-induced suppression of NK activity has been 
observed in adrenalectomized animals and in animals treated with glucocorticoid antagonists 
(Bayer et al., 1990b; Fecho et al., 1996b; Liang-Suo et al., 2002).  On the other hand, 
sympathetic efferent pathways have been implicated based on indirect evidence showing that 
opioid administration increases central sympathetic outflow (Appel et al., 1986), and 
activation of the sympathetic nervous system by various stimuli suppresses splenic NK 
activity (Fecho et al., 1993b; Irwin et al., 1990; Jiang et al., 2004; Wu and Pruett, 1996b).  
Furthermore, the PAG—a  region closely associated with the regulation of sympathetic 
outflow—has been identified as a site of morphine’s µ-opioid receptor interactions 
responsible for the suppression of NK cell activity (Lysle et al., 1996; Weber and Pert, 1989). 
In conclusion, the present study provides the first demonstration that the nucleus accumbens 
is involved in opioid-induced immunosuppression.  Overall, these data provide substantial 
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evidence for the involvement of endogenous dopamine pathways in opioid mediated 
immunosuppression and further suggest that opioid-induced increases in dopamine signaling 
may have adverse consequences on immune status.  Given that the capacity to increase 
dopamine transmission is a common property of drugs of abuse, these findings may have 
important implications regarding the mechanisms through which abused drugs compromise 
host defenses.  
 
 
 
 
 
CHAPTER 3 
 
NEUROPEPTIDE Y-DEPENDENT MECHANISMS OF OPIOID-INDUCED 
IMMUNOMODULATION 
 
 
 
 
Introduction 
The previous chapter presented evidence that the stimulation of dopamine D1 
receptors in the nucleus accumbens shell is necessary to produce opioid-induced decreases in 
splenic NK cell activity and iNOS expression.  The studies described in the current chapter 
will examine how these central effects of opioids translate into peripheral immune alterations 
by evaluating the role of the sympathetic peptide transmitter neuropeptide Y (NPY).  
Although peripheral mediators responsible for the effects of opioids on certain immune 
measures have been identified, the receptor mechanisms that underlie effects on NK cytolytic 
activity and iNOS production have not been established.  The primary pathways whereby 
centrally acting opioids modulate peripheral immune responses involve the sympathetic 
nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis.  In general, the 
sympathetic nervous system mediates immune alterations induced by acute opioid exposure, 
whereas the HPA axis appears to be involved in the immunological effects that result from 
chronic opioid exposure. 
Sympathetic nerve fibers directly innervate primary and secondary lymphoid organs 
and have even been shown to form synaptic-like contacts with splenic lymphocytes (Felten et 
al., 1985; Felten and Olschowka, 1987).  Activation of the SNS results in the release of 
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catecholamines, which can modulate immune status directly via activation of cell surface 
immunocyte adrenoceptors.  Several of the immunomodulatory effects induced by morphine 
are mediated by β-adrenoceptors specifically.  For instance, β-adrenoceptor antagonists block 
the inhibitory effect of morphine on splenocyte proliferative responses to T and B cell 
mitogens (Fecho et al., 1993a).  Catecholamines have also been reported to modulate NK cell 
activity via β2-adrenoceptors (Irwin et al., 1990; Takamoto et al., 1991), but morphine-
induced inhibition of NK responses appears to involve different mechanisms.  Studies which 
have employed peripherally acting adrenergic antagonists show that neither the β-receptor 
antagonist nadolol (Fecho et al., 1993a), nor the α-receptor antagonist doxazosin (Carr et al., 
1994b) prevent morphine’s inhibitory effect on NK activity.  Other investigations of SNS 
involvement in the effects of morphine have shown that the ganglionic blocker 
chlorisondamine does not prevent reductions in NK activity, but since chlorisondamine alone 
inhibits NK activity it is difficult to draw conclusions regarding the mechanisms of 
morphine’s effect (Fecho et al., 1996b).  In sum, there is no conclusive evidence that either 
glucocorticoids or peripheral catecholamines are responsible for the suppressive effect of 
acute morphine exposure on NK activity.   
Several lines of evidence indicate that NPY may be an important modulator of splenic 
NK cell activity.  Immunocytochemical have revealed the presence of NPY in postganglionic 
sympathetic fibers that innervate the spleen (Romano et al., 1991).  Activation of the 
sympathetic nervous system causes the release of NPY, which in turn induces a host of 
immunomodulatory effects.  Notably, circulating NPY levels, but not catecholamines, were 
inversely correlated with NK activity in Alzheimer’s caregivers, suggesting that NPY may 
modulate NK activity under physiological conditions in vivo.  Further support for this 
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hypothesis was provided by the demonstration that NPY produces a direct and dose-
dependent inhibition of NK activity in vitro (Nair et al., 1993).  Although the mechanism of 
the effect of NPY on NK cells is not fully understood, the discovery of functional NPY Y1 
receptors on rat splenic lymphocytes offers the possibility that NPY may interact directly 
with its cognate receptors on NK cells to suppress cytolytic activity (Bedoui et al., 2002; 
Petitto et al., 1994). 
An important finding revealed in chapter 2 is that opioid-induced immune alterations 
which are dependent on central dopamine D1 receptor activation (i.e., reduced NK activity 
and iNOS expression), are distinct from the immune alterations mediated by peripheral β-
adrenergic receptors (i.e., decreased lymphocyte proliferative responses).  In the present 
chapter, we examine the hypothesis that NPY mediates the dopamine-dependent effects of 
morphine and heroin on immune status.  The first study evaluates the role of NPY Y1 
receptors in morphine-induced alterations of splenic lymphocyte proliferation and NK cell 
activity. The second study assesses the effect of intravenous NPY administration to 
determine whether increased levels of NPY are sufficient to alter immune parameters in vivo.  
A third study was performed to determine whether direct stimulation of nucleus accumbens 
D1 receptors regulates NK activity through a peripheral NPY Y1 receptor mechanism.  
Finally, the current chapter examines the role of NPY Y1 receptors in heroin-induced 
reductions of iNOS expression using the LPS model of Gram-negative sepsis. 
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Materials and Methods 
Animals 
 Adult male Lewis rats weighing approximately 200-250 grams were purchased from 
Charles River Laboratories (Raleigh, NC).  Upon arrival, animals were individually housed 
and maintained on a reverse 12-hr light/dark cycle.  Animals were habituated to handling and 
the colony room environment for two weeks prior to any experimental manipulation.  Food 
and water were available ad libitum throughout the experiment. 
 
Drugs 
Morphine sulfate (NIDA, Bethesda, MD), R(+)-SKF-38393 hydrochloride (Sigma-
Aldrich, St. Louis, MO), and Neuropeptide Y (AnaSpec,  San Jose, CA) were dissolved in 
sterile 0.9% saline.  BIBP3226 (Sigma) was dissolved in sterile water.  For all experiments, 
morphine was administered s.c. at a dose of 15 mg/kg in a 1.0 ml/kg volume. 
   
Surgical and Drug Administration Procedures 
In the first experiment rats were assigned to one of six groups (n = 3-4 per group) in 
which they received the NPY Y1 receptor antagonist BIBP3226 (0, 0.1, or 1.0 mg/kg, s.c.) 30 
minutes prior to saline or morphine.  Animals were sacrificed one hour following morphine 
or saline administration and spleens were collected for immunological assessments.  This 
time point was selected based on previous data from our laboratory indicating a maximal 
suppression of the measured immune parameters 1 h following morphine administration.  
This experiment was replicated using the same design, and the data was combined for 
analysis (n = 7 – 8 per group). 
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In the second experiment rats were assigned to one of five groups (n = 4) in which they 
received NPY (0, 0.2, 2, 20, or 200 µg, i.v.) on the test day.  Catheterization surgeries were 
performed under anesthesia induced with a 0.2 ml intramuscular injection of a 1:1 (vol/vol) 
mixture of ketamine (100 mg/ml) and xylazine (20 mg/ml).  Catheters made of flexible 
silastic tubing were inserted into the right jugular vein and secured with ligatures around the 
catheterized vessel. The tubing was tunneled subcutaneously and exteriorized on the dorsal 
side to allow injection of drugs.  A stay suture placed beneath the skin in the scapular region 
maintained the position of the catheter, and the excess tubing was tucked into a subcutaneous 
skin pocket made cranial to the scapulae. The exterior portion of the catheter was held in 
place with two stainless steel suture clips.   Patency was tested, and the catheter was filled 
with 0.2 ml of heparinized dextrose locking solution and sealed with a stainless steel plug. 
Animals were given a one-week recovery period prior to drug administration.  On the test 
day animals received an i.v. injection of NPY or saline in a 200 µl injection volume, 
followed by a 300 µl injection of saline to flush through any drug remaining in the tubing.  
Animals were sacrificed one hour following NPY administration for assessment of immune 
parameters.  This experiment was replicated using the same design, and the data was 
combined for analysis (n = 8 per group) 
For the third experiment, stereotaxic surgeries were performed under anesthesia as 
described above.  Animals receiving SKF-38393 administration into the nucleus accumbens 
shell were implanted with bilateral 26-gauge guide cannulae (Plastics One, Roanoke, VA) 
aimed at the following coordinates:  AP +1.7, ML ±1.0, DV –5.4.  Coordinates are expressed 
as millimeters from bregma (Paxinos and Watson, 1986).  Animals were given a one-week 
recovery period prior to drug administration.  On the test day, animals were assigned to one 
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of four groups (n = 4) in which they received an injection of saline or BIBP3226 (1 mg/kg, 
s.c.) 30 minutes prior to a bilateral injection of SKF-38393 (0 or 0.5 µg/ side).  One hour 
following SKF-38393 administration, animals were sacrificed and spleens were collected for 
assessment of immune status.  This experiment was replicated twice using the same design, 
and the data was combined for analysis (n = 8 per group).  SKF-38393 was administered in a 
0.5 µl volume per side via a 33-gauge injector that protruded 2 mm beyond the tip of the 
guide cannula (final coordinates: AP +1.7, ML ±1.0, DV –7.4).  Intracranial drug 
microinjections were performed over a 30 second period using a microsyringe pump 
(Harvard Apparatus, Holliston, MA) and the injector was left in place for one minute to 
allow diffusion of the drug away from the injection site.  Following drug treatment and 
sacrifice, Alcian Blue dye was injected via the cannula and brains were removed and post-
fixed in 4% paraformaldehyde for two days.  Brains were transferred to a 30% sucrose 
solution for cryoprotection, frozen, and stored at -80˚C for subsequent analysis.  Accurate 
cannulae placements were verified by examination of 50 µm thionin-stained tissue sections 
under a light microscope.  Only animals with placements within the targeted region were 
included in the analysis. 
 
Tissue Collection 
 Following sacrifice, spleens were removed and prepared as a single-cell suspension as 
described in detail in Chapter 2.  Splenic leukocytes were counted using a Hemavet 850 cell 
analyzer (CDC Technologies Inc., Oxford, CT), and cell suspensions were adjusted to 5 × 
106 leukocytes/ml. 
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Natural Killer Cell Assay 
 Splenic NK cell activity was assessed using a standard chromium release assay.  A 
detailed description of the assay is provided in Chapter 2. 
 
Splenocyte Proliferation Assay 
Splenocyte proliferative responses were assessed using mitogen stimulation assays.  
A detailed description of the assay is provided in Chapter 2. 
 
Real-Time RT-PCR 
The expression of iNOS mRNA was quantified using real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) as described in detail in Chapter 2. 
 
Statistics 
Data analysis for the experiments involving morphine and heroin administration were 
performed using a two-way analysis of variance (ANOVA) to assess the impact of BIBP3226 
pretreatment on the effect of opioid injection.  For the two-way analysis, the first factor was 
dosage of BIBP3226 and the second factor was the type of subsequent injection 
(morphine/heroin or saline).  Experimental replication was entered into the model as a 
covariate to control for inter-assay variability in the measured parameters.  Data from the i.v. 
NPY administration study was analyzed using a one-way ANOVA to assess the effect of 
NPY dosage, with experimental replication included as a covariate.  For the third experiment, 
a two-way ANOVA was utilized.  The first factor was dosage of BIBP3226 and the second 
factor was the dosage of SKF-38393.  Again, experimental replication was entered into the 
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model as a covariate to control for inter-assay variability.  For all analyses, general contrast 
comparisons were performed in accordance with a priori hypotheses.  All analyses were 
performed with the level of significance set at p < 0.05. 
 
Results 
NPY Y1 Receptor Antagonism:  Morphine-Induced Effects  
The first study examined whether antagonism of NPY Y1 receptors with BIBP3226 
prevented the effect of morphine on immune status.  Figure 3.1 shows the effect of 
BIBP3226 on morphine-induced suppression of NK activity.  Morphine produced a 
significant decrease in splenic NK cell activity as determined by planned comparisons 
between the vehicle/saline and vehicle/morphine treatment groups [F(1, 33) = 18.06; p < 
.001].  Analysis of variance revealed a significant interaction between morphine treatment 
and dose of BIBP3226 [F(2, 33) = 6.75; p < .01],  indicating that the suppressive effect of 
morphine was reduced by BIBP3226 administration.  Furthermore, planned contrasts 
revealed that Y1 receptor antagonism altered the suppressive effect of morphine, as the 
groups that received BIBP3226 (0.1 or 1.0 mg/kg) prior to morphine were not significantly 
different from the corresponding saline groups. 
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Figure 3.1  Effect of NPY Y1 receptor antagonism on morphine-induced suppression of 
splenic NK activity.  Subcutaneous administration of the Y1 antagonist BIBP3226 reversed 
the inhibitory effect of morphine on NK activity.  Data are expressed as lytic units (mean ± 
S.E.).  **p < .001 compared with the saline group that received the same dose of BIBP3226. 
 
 
 
Figure 3.2 shows the effect of BIBP3226 on morphine-induced suppression of 
splenocyte mitogenic responses to Con-A and LPS.   Morphine suppressed proliferation 
induced by Con-A (Figure 3.2, left panel) as revealed by a significant main effect of 
morphine treatment [F(1, 33) = 111.84; p < .0001].  LPS-induced mitogenesis (Figure 3.2, 
right panel) was also significantly reduced by morphine administration [F(1, 33) = 28.62; p < 
.0001].   There was not a significant main effect of BIBP3226 treatment on proliferative 
responses to Con-A [F(2, 33) = 0.03; p > .05] or LPS [F(2, 33) = 0.78; p > .05], nor was 
there a significant BIBP3226 by morphine dose interaction in either analysis.  Furthermore, 
BIBP3226 administration did not block the effect of morphine at any dose tested, as planned 
comparisons indicated that each morphine treated group displayed significantly lower 
proliferation compared to the corresponding saline group that received an equivalent dose of 
antagonist (ps < .05). 
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Figure 3.2  Effect of NPY Y1 receptor antagonism on morphine-induced suppression of 
splenic lymphocyte proliferation.  Subcutaneous BIBP3226 administration did not attenuate 
the inhibitory effect of morphine on splenocyte mitogenic responses to Con-A (5.0 µg/ml) or 
LPS (5.0 µg/ml) stimulation.  Data are expressed as disintegrations per minute (mean ± S.E.).  
*p < 0.05; **p < .001 compared with the saline group that received the same dose of 
BIBP3226. 
 
 
 
 
Exogenous NPY Administration 
The second experiment was carried out to examine the effect of intravenous NPY 
administration on immune status.  The results of the NK assay displayed in Figure 3.3 (left 
panel) show that NPY produced a dose-dependent reduction in splenic NK activity.  Analysis 
of variance indicated a significant main effect of NPY dosage [F(4, 33) = 16.23; p < .0001].  
Polynomial contrasts showed a highly significant linear component to the drug treatment 
[F(1, 33) = 58.08; p < .0001], indicating that the suppressive effect of NPY on NK cytolytic 
activity increased in a dose-dependent manner. 
Figure 3.3 displays the effect of i.v. NPY administration on splenocyte proliferative 
responses to Con-A (middle panel) and LPS (right panel).  The analysis revealed that NPY 
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treatment did not have a significant effect on splenocyte mitogenesis induced by Con-A [F(4, 
32) = 1.53; p > .05].  Although there appeared to be a trend of increased Con-A induced 
proliferation in the groups receiving the two highest doses of NPY, planned comparisons 
revealed no significant differences between the saline and NPY-treated groups at any dose of 
NPY.  There was a significant main effect of NPY dosage on LPS induced splenocyte 
proliferation [F(4, 32) = 2.69; p < .05].  Polynomial contrasts revealed a significant linear 
component [F(1, 32) = 5.11; p < .05] suggesting that NPY increased proliferation.  However, 
planned comparisons between the saline group and each NPY-treatment group failed to 
reveal a significant between-group difference on LPS-induced proliferation at any dose of 
NPY. 
 
 
 
Figure 3.3  Effect of NPY administration on splenocyte immune measures.  Intravenous 
administration of NPY reduced splenic NK cell activity in a dose-dependent manner (left 
panel).  NPY administration did not suppress lymphocyte proliferative responses to Con-A 
(middle panel) or LPS (right panel) stimulation.  Data from the cytotoxicity assay data are 
expressed as lytic units (mean ± S.E.).  Data from proliferation assays are expressed as 
disintegrations per minute (mean ± S.E.).  **p < .0001 compared to saline treatment. 
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NPY Y1 Receptor Antagonism:  Dopamine Agonist-Induced Effects 
Data presented in Chapter 2 showed that morphine’s effect on splenic NK activity is 
mediated through dopamine D1 receptor activation in the nucleus accumbens shell.   
Moreover, injection of the D1 agonist SKF-38393 into this region was shown to mimic the 
suppressive effect of morphine on NK activity.  Based on those findings, we investigated 
whether agonist stimulation of accumbens D1 receptors would produce an NPY Y1 receptor-
mediated inhibition of NK cell activity.  Figure 3.4 displays the effect of BIBP3226 on D1 
agonist-induced reductions of NK activity.  Planned comparisons demonstrated that SKF-
38393 administration significantly reduced NK activity in animals that received 
subcutaneous saline injections [F(1, 27) = 48.30; p < .0001]  Analysis of variance revealed a 
significant interaction between SKF-38393 and BIBP3226 treatments [F(1, 27) = 33.97; p < 
.0001],  indicating that the suppressive effect of SKF-38393 was attenuated by BIBP3226 
pretreatment.  Furthermore, planned contrasts revealed that BIBP3226 completely blocked 
the suppressive effect of SKF-38393, as there was no significant difference between saline 
and SKF-38393 treatment groups among animals pretreated with BIBP3226 [F(1, 27) = 1.66; 
p > .05].   These findings show that systemic BIBP3226 administration prevents the 
suppression of NK activity induced by stimulation of D1 receptors in the nucleus accumbens 
shell. 
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Figure 3.4  Effect of NPY Y1 receptor antagonism on NK activity in rats that received 
microinjections of the dopamine D1 receptor agonist SKF-38393 into the nucleus accumbens 
shell.  Rats received a subcutaneous injection of BIBP3226 or vehicle prior to microinjection 
of saline or SKF-38393.  Administration of BIBP3226 prevented the suppression of NK 
activity induced by SKF-38393 microinjection.  Data are expressed as lytic units (mean ± 
S.E.).  **p < .0001 compared to the vehicle-saline control group. 
 
 
 
NPY Y1 Receptor Antagonism:  Heroin-Induced Effects 
 
A final study examined whether NPY Y1 receptors play a role in the effects of heroin 
on iNOS production in vivo.  LPS-induced expression of iNOS mRNA in spleen, liver, and 
lung tissues is shown in Figure 3.5.  Planned comparisons demonstrated that heroin 
significantly reduced iNOS levels compared to saline in the spleen [F(1, 37) = 5.66; p < .05] 
and  liver [F(1, 37) = 6.54; p < .05] among animals that received vehicle injections but did 
have a significant effect on lung iNOS expression [F(1, 37) = 0.99; p > .05].  Analysis of 
variance revealed a significant main effect of BIBP3226 dosage in the spleen [F(2, 37) = 
5.57; p < .01] and lung [F(2, 37) = 4.10; p < .05].  Although the overall interaction between 
BIBP3226 dosage and heroin treatment was significant in only the liver [F(2, 37) = 3.29; p < 
.05], polynomial contrasts showed a significant linear interaction in the spleen [F(1, 37) = 
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4.50; p < .05], liver [F(1, 37) = 6.57; p < .05], and lung [F(1, 37) = 4.34; p < .05] indicating 
that BIBP3226 altered the effect of heroin in all three tissues.  Importantly, planned 
comparisons between heroin and saline treated groups that received 0.1 or 1.0 mg/kg BIBP 
showed no significant in the spleen, liver, or lung (ps > .05).  Overall, these results indicate 
that BIBP3226 abolished heroin’s suppressive effect on iNOS expression in the spleen and 
liver. 
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Figure 3.5  Effect of NPY Y1 receptor antagonism on heroin-induced alterations of iNOS 
mRNA expression.  Rats received subcutaneous injections of BIBP3226 prior to saline or 
heroin in conjunction with LPS administration.  BIBP3226 prevented the suppressive effect 
of heroin on iNOS expression in the spleen and liver.  Data are expressed as the ratio of 
iNOS mRNA expression to expression of the housekeeping gene cyclophilin (mean ± S.E.).  
*p < .05 compared to the vehicle-saline control group. 
 
 
 
Discussion 
The present study demonstrates that administration of the selective NPY Y1 receptor 
antagonist BIBP3226 prevents the suppressive effects of acute opioid exposure on splenic 
NK cell activity and the production of iNOS.  Opioid-induced effects on various immune 
parameters such as NK cytolytic responses do not occur via direct interactions between 
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opioids and immune cells but rather as an indirect consequence of µ-opioid receptor 
stimulation in the CNS (Fecho et al., 1996a; Shavit et al., 1986; Weber and Pert, 1989).  
Glucocorticoids and catecholamines have been identified as the major peripheral mediators 
that directly modulate immunocyte functions in response to signals from the nervous system. 
Glucocorticoids have been shown play an important role in the immunomodulatory effects 
induced by chronic morphine exposure, but they do not appear to mediate the effects of acute 
morphine administration.  For example, the glucocorticoid receptor antagonist mifepristone 
blocks the decrease of NK activity in mice implanted with morphine pellets (Freier and 
Fuchs, 1994), but neither mifepristone nor adrenalectomy block the reduction in NK activity 
following acute morphine exposure (Fecho et al., 1996b; Liang-Suo et al., 2002).  Moreover, 
mifepristone does not prevent the effect of acute morphine administration on the proliferative 
responses of blood, splenic, or thymic lymphocytes (Bayer et al., 1990b; Liang-Suo et al., 
2002). 
Catecholamines, which are released from sympathetic nerves, have been implicated in 
many of morphine’s acute immunomodulatory effects.  For example, acute morphine 
administration suppresses the proliferative responses of splenic lymphocytes to concanavalin 
A (Con-A), lipopolysaccharide (LPS), phytohemagglutinin (PHA), and ionomycin/phorbol 
myristate acetate (PMA); and these effects are all prevented by pretreatment with β-
adrenergic receptor antagonists (Fecho et al., 1993a).  However, acute morphine-induced 
reductions in splenic NK cell activity are not blocked by either peripheral adrenergic receptor 
antagonists or adrenalectomy, suggesting than neither the HPA axis nor sympathetic 
catecholamines are involved (Carr et al., 1994b; Fecho et al., 1993a; Fecho et al., 1996b).  
Still, sympathetic mechanisms have been implicated based on indirect evidence showing that 
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morphine increases central sympathetic outflow (Appel et al., 1986) and that activation of the 
sympathetic nervous system by a diverse array of stimuli suppress splenic NK activity.  Thus, 
it is likely that multiple sympathetic mechanisms are involved in the regulation of NK cell 
activity. 
 In addition to catecholamines, NPY is another important sympathetic transmitter that 
modulates a host of immunological parameters.  The present study indicates that NPY 
mediates morphine-induced reductions of splenic NK activity via peripheral Y1 receptors, as 
BIBP3226 reportedly does not penetrate the blood-brain barrier (Doods et al., 1996).  Given 
that NPY suppresses NK activity in vitro (Nair et al., 1993), it is very possible that Y1 
receptors located on NK cells mediate the observed effects, although future studies are 
needed to resolve this issue.  The current study also shows that intravenous NPY 
administration induces a suppression of NK activity, further supporting an in vivo role for 
NPY in modulating NK responses.  The finding that both the 20 µg and 200 µg doses of NPY 
induced a comparable suppression indicates that the 20 µg dose is sufficient to produce the 
maximal inhibitory effect of NPY (an approximately 50% decrease) on NK activity.  
Interestingly, NPY not only inhibits splenic NK activity directly, but central NPY 
administration has also been shown to suppress NK responses (von Horsten et al., 1998).  
Although the intravenous route of NPY administration does not completely differentiate 
between central and peripheral sites of action, peripheral NPY apparently does alter NK cell 
responses in vivo, as evidenced by the ability of BIBP3226 to block morphine’s inhibitory 
effect on NK cell activity.  The current findings support the hypothesis that the SNS mediates 
the acute immunomodulatory effects of opioids and further suggests that NPY does not 
simply potentiate the effect of catecholamines on NK responses since Y1 receptor antagonism 
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completely prevented the suppression of NK activity.  Both catecholamines and NPY 
administration have been shown to modulate NK cytotoxicity and these effects appear to 
occur through distinct receptor mechanisms.   An important question for future studies to 
address is the conditions under which catecholamines or NPY modulate NK activity.  
 The results of the present study show that Y1 receptor antagonism does not attenuate 
morphine’s effect on splenocyte proliferative responses to Con-A or LPS, nor did 
intravenous NPY administration suppress splenocyte proliferation.  This is consistent with 
previous demonstrations indicating that β-adrenergic receptors mediate morphine’s effects on 
lymphocyte proliferative responses (Fecho et al., 1993a).  Although our findings suggest that 
NPY is not involved in the effects of morphine on lymphocyte proliferation, NPY has been 
shown to alter a number of other T and B cell activities including T cell production of IL-2 
(Medina et al., 2000), and specific antibody responses to keyhole limpet hemocyanin 
(Friedman et al., 1995).  Thus, it is possible that more subtle and sensitive measures of T and 
B cell status will reveal additional modulatory effects of NPY on morphine-induced immune 
alterations.  Intravenous NPY administration did produce a slight overall enhancement of 
LPS induced proliferation, but it should be noted that planned pairwise comparisons with the 
saline control group and each NPY dose group failed to reveal a significant effect of NPY at 
any individual dose.  It is possible that intravenously administered NPY produces indirect 
effects on lymphocyte proliferative responses by altering the composition or density of 
lymphocytes in the spleen.  For example, intravenous NPY administration has been shown to 
alter blood leukocyte numbers in a dose-dependent manner (Bedoui et al., 2001).  Thus, 
potential effects of NPY on the distribution of splenic B-cells offers one potential 
explanation for the slight alterations of LPS induced proliferation.  It is important to 
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emphasize however, that with respect to the effects of morphine, neither the total number of 
splenic leukocytes nor the relative numbers of lymphocyte subtypes are altered (Fecho and 
Lysle, 1999).  Therefore, it is unlikely that the mobilization of NK cells in response to 
increased endogenous NPY levels accounts for morphine’s effects on NK activity since 
spleen NK cell numbers do not change following morphine administration anyway (Fecho 
and Lysle, 1999). 
 The discrepancy between the peripheral receptor mechanisms involved in morphine’s 
effect on NK activity and lymphocyte proliferative responses provides an intriguing example 
of the ability of the nervous system to selectively modulate discrete immunological 
parameters.  Just as precise neural circuits are involved in a particular behavioral response, 
specific neural circuits also regulate discrete immunological responses.  Data presented in the 
previous chapter showed that the nucleus accumbens shell is critically involved in mediating 
the effects of morphine on NK activity.  Specifically, intra-accumbens injections of the 
dopamine D1 receptor antagonist SCH-23390 was shown to block the effect of morphine and 
heroin on NK activity but not lymphocyte proliferation, whereas administration of the D1 
agonist SKF-38393 into the accumbens suppressed NK activity similarly to morphine but did 
not alter splenocyte mitogenesis.  The neuroimmune efferent pathway through which nucleus 
accumbens dopamine receptor activation leads to altered splenic NK responses has not yet 
been characterized, but the close association with the nucleus accumbens to areas involved in 
autonomic regulation suggest that sympathetic efferent pathways may be involved.  The 
results of the present study indicate that pretreatment with a peripherally acting Y1 receptor 
antagonist prevents the suppression of NK activity induced by D1 agonist administration into 
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the nucleus accumbens shell.  These findings suggest that the activation of D1 receptors in the 
accumbens inhibits NK activity by increasing the peripheral release of NPY. 
 The present study also shows that Y1 receptor blockade prevents heroin-induced 
reductions of iNOS expression in the spleen and liver.  Taken together with our previous data 
showing that heroin’s effect on iNOS expression requires the activation of D1 receptors in the 
nucleus accumbens, the current findings suggest that the production of iNOS in response to 
LPS involves the same neural mechanisms responsible for opioid-induced alterations of NK 
cell activity.  It should be noted that in the present investigation, although there was a trend 
toward suppression in the lung, heroin did not have a significant effect on iNOS in this tissue.  
The reason for a lack of effect in the lung tissue only is not immediately apparent.  Typically, 
the spleen and liver show the most robust effect of iNOS expression, but prior investigations 
such as those presented in the previous chapter do show that heroin inhibits lung iNOS levels 
under similar experimental parameters.  It is possible that the batch of LPS used in the 
present studied varied in potency, or that perhaps there were ancillary stress effects in the 
colony room on the day of the experiment.  In any case, the findings that heroin-induced 
reductions of iNOS in the spleen and liver are abolished by BIBP3226 suggest that NPY 
plays an important role in the in vivo immunological effects of heroin.  Furthermore, these 
data provide additional evidence for the hypothesis that NPY is a peripheral mediator of the 
dopamine-dependent immunomodulatory effects of opioids. 
 The SNS modulates the immune system by regulating sympathoadrenal activity or 
through direct innervation of lymphoid organs.  Acute morphine administration has been 
shown to increase plasma catecholamine levels by activating central sympathetic outflow 
(Appel et al., 1986).  Sympathoadrenal activity appears to mediate morphine’s suppressive 
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effect on lymphocyte mitogenic responses, because both adrenalectomy and β-adrenoceptor 
antagonists block this effect (Fecho et al., 1993a; Fecho et al., 1996b).  Since adrenalectomy 
does not alter morphine’s effect on NK activity, it is unlikely that adrenally derived NPY 
mediates the NK cell suppression.  As no studies have examined the peripheral mechanisms 
of opioid-induced effects on iNOS production, the adrenals cannot be ruled out as a potential 
source of NPY responsible for effects on spleen and liver iNOS levels.  However, 
adrenalectomy in the rat has been shown to reduce the increase in plasma epinephrine elicited 
by stress without concomitant effects on increased NPY levels, indicating that the adrenals 
are not a major source of circulating NPY (Mormede et al., 1990).  Thus, nucleus accumbens 
D1 receptor activation may modulate splenic NK activity and iNOS expression by increasing 
the activity of NPY-releasing sympathetic nerves, but this effect does not seem to involve 
sympathoadrenal activity.  Further studies are needed to determine whether opioids alter 
immune measures by increasing the local release of NPY in target tissues such as the spleen 
and liver specifically. 
 Collectively, data from the present study along with the results of prior investigations 
strongly suggest that the stimulation of CNS µ-opioid receptors following acute opioid 
administration produces immune alterations via the SNS.  Evidence shows that opioid-
induced reductions of splenic NK cell activity and LPS-induced iNOS expression are 
mediated peripherally by NPY Y1 receptors, whereas morphine’s effects on splenic T and B 
cell proliferative responses to Con-A and LPS are mediated by peripheral β-adrenoceptors.  
The adrenal medulla appears to be the source of catecholamines that activate β-adrenoceptors 
to inhibit splenocyte proliferative responses, whereas the peripheral source of NPY that 
modulates immune parameters via Y1 receptors is not the adrenal medulla but possibly 
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sympathetic nerves such as those that innervate the spleen and liver.  The results of the 
current and prior studies further suggest that opioid administration induces the activation of 
dopamine D1 receptors in the nucleus accumbens shell, leading to the suppression of NK cell 
activity and iNOS production as a result of increased NPY release from sympathetic nerves. 
 
 
 
 
 
 
CHAPTER 4 
 
NEUROIMMUNE MECHANISMS OF OPIOID-MEDIATED CONDITIONED 
IMMUNOMODULATION 
 
 
 
 
Introduction 
The results presented in chapters 2 and 3 characterized novel central and peripheral 
mechanisms that underlie the pharmacological effects of opioids on splenic NK cell activity 
and nitric oxide production.  Those findings suggest that opioid-induced stimulation of 
dopamine D1 receptors in the nucleus accumbens shell produces peripheral immune 
alterations by increasing NPY release from sympathetic nerves.  The current chapter draws 
on the knowledge gained from the previous chapters to examine whether similar receptor 
mechanisms mediate the conditioned effects of opioids on the immune system.  This chapter 
is based on our recent publication (Saurer et al., in press). 
Pavlovian (classical) conditioning of immune responses is a truly fascinating 
illustration of the dialogue between the brain and the immune system in which the brain 
associates a novel cue with concomitant immunological changes and subsequently 
reproduces those precise immune changes when re-exposed to the cue at a later point in time.  
The basic paradigm involves paired presentations of an initially neutral conditioned stimulus 
(CS), such as a novel taste or context, with a stimulus that actively evokes an 
immunomodulatory response, termed the unconditioned stimulus (UCS).  Upon repeated CS-
UCS pairings, re-exposure to the CS alone (i.e., in the absence of the UCS) alters immune 
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functioning in a manner which mimics the normal or unconditioned effect of the UCS.  
Investigators have successfully employed a variety of unconditioned stimuli to demonstrate 
that a broad range of immune measures are susceptible to Pavlovian conditioning, including 
both innate and adaptive responses (for reviews see Ader and Cohen, 2001; Kusnecov et al., 
1989).   
While Pavlovian conditioning of immune responses has been established in a number 
of models, only a limited number of studies have investigated the biological mechanisms of 
this phenomenon.  The precise mechanisms undoubtedly differ depending on the nature of 
the UCS as well as that of the CS, but the opioid system appears to play an important role in 
several paradigms.  The presentation of a CS previously paired with aversive electric shock 
produces conditioned stress-induced reductions in NK cell activity and lymphocyte mitogenic 
responses that are mediated by endogenous opioids (Lysle et al., 1992a).  These conditioned 
immune alterations were later shown to be mediated specifically by µ-opioid receptors in the 
CNS, providing direct evidence for the involvement of the central opioid system in 
conditioned immunomodulation (Perez and Lysle, 1997).   
The pharmacological effects of exogenous opioids can also be conditioned to 
environmental stimuli.  For example, when rats are re-exposed to a distinctive environment 
associated with morphine administration, immunological alterations occur that are similar to 
those produced by the drug alone, including decreased mitogen responsiveness of blood and 
splenic lymphocytes, reduced interleukin-2 production, and decreased NK cell activity in the 
spleen (Coussons et al., 1992).  Previous studies have established that these conditioned 
effects are due to the learned psychological state induced by the CS, as development of the 
conditioned immunomodulatory response requires the explicit pairing of morphine 
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administration with the CS and is not attributable to ancillary effects of the conditioning 
procedure (Coussons et al., 1992).  Importantly, it has been recently demonstrated that the 
conditioned effects of heroin on nitric oxide expression are susceptible to extinction and 
latent inhibition, indicating that opioid-conditioned immune alterations conform to major 
principles of associative learning (Szczytkowski and Lysle, 2007).  Given that conditioned 
immune alterations modify disease progression in numerous models of clinical disease (e.g., 
Ader and Cohen, 1982; Exton et al., 1998; Klosterhalfen and Klosterhalfen, 1983; Lysle et 
al., 1992b), an important implication is that—in addition to the pharmacological effects of 
opioids—any detrimental health consequences of opioid use may also be conditioned to 
environmental stimuli associated with the drug. 
There is accumulating evidence that the conditioned effects of morphine on immune 
status are mediated by neural processes similar to those which underlie the drug’s 
pharmacological effects. For example, both conditioned and unconditioned 
immunomodulatory effects of morphine are initiated by the activation of central opioid 
receptors and involve increased activity of the sympathetic nervous system (Coussons-Read 
et al., 1994a; Coussons-Read et al., 1994b; Fecho et al., 1996b).  The sympathetic nervous 
system provides a “hardwired” neuroimmune communication pathway as sympathetic fibers 
directly innervate lymphoid organs and form synaptic-like contacts with splenic lymphocytes 
(Felten et al., 1985; Felten and Olschowka, 1987).  Thus, activation of sympathetic nerves 
directly modulates immune status via the release of catecholamines and neuropeptide Y 
(NPY), which interact with immunocyte cell surface receptors.  Sympathetic efferent nerves 
appear to be the major neuroimmune pathway responsible for alterations in peripheral 
immune parameters induced by morphine and morphine-conditioned stimuli.  For instance, 
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administration of the peripherally acting β-adrenoceptor antagonist nadolol abolished both 
the conditioned and unconditioned effects of morphine on splenocyte proliferative responses 
to T and B cell mitogens (Coussons-Read et al., 1994b; Fecho et al., 1993a).  However, these 
studies reported that neither the conditioned nor unconditioned effects of morphine on 
splenic NK cell activity are attenuated by antagonism of β-adrenoceptors. 
The findings presented in the previous chapters demonstrate that the pharmacological 
effect of morphine on NK cell activity is mediated by mechanisms distinct from those which 
govern decreases in lymphocyte proliferation.  Specifically, it was shown that the activation 
of dopamine D1 receptors in the nucleus accumbens shell is necessary for morphine-induced 
suppression of splenic NK activity and that peripheral NPY Y1 receptors mediate these 
dopamine-dependent effects (Saurer et al., 2006b).  However, whether similar mechanisms 
play a role in conditioned immunomodulation is unknown.  The goal of the present study was 
to determine whether exposure to a CS previously associated with morphine would elicit 
conditioned immunomodulatory effects by acting via similar dopamine and NPY receptor-
dependent mechanisms.  To address this issue, we evaluated the effects of the dopamine D1 
antagonist SCH-23390 and the NPY Y1 antagonist BIBP3226 on the expression of 
conditioned immune alterations which were induced by environmental stimuli previously 
paired with the administration of morphine. 
 
Materials and Methods 
Animals 
 Adult male Lewis rats weighing approximately 200-250 grams were purchased from 
Charles River Laboratories (Raleigh, NC).  Upon arrival, animals were individually housed 
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and maintained on a reverse 12-hr light/dark cycle.  Animals were habituated to handling and 
the colony room environment for two weeks prior to any experimental manipulation.  Food 
and water were available ad libitum throughout the experiment. 
 
Drugs 
Morphine sulfate (NIDA, Bethesda, MD) and R(+)-SCH-23390 hydrochloride 
(Sigma-Aldrich, St. Louis, MO) were dissolved in sterile 0.9% saline.  For all experiments, 
morphine was administered subcutaneously at a dose of 15 mg/kg in a 1.0 ml/kg volume.  
This dose was selected based on previous studies from our laboratory showing that the 
effects of morphine are dose-dependent and that the effects were blocked by naltrexone, 
indicating the involvement of opioid receptors (Lysle et al., 1993).  BIBP3226 (Sigma) was 
dissolved in sterile water. 
 
Conditioning Procedures 
 The conditioning apparatus consisted of standard rodent conditioning chambers 
individually contained within sound-attenuating cubicles.  The conditioning chambers 
provided distinctive visual (stainless steel and Plexiglas walls), tactile (wire grid floors), 
auditory (white noise), and olfactory (cedar chips) cues to distinguish this environment from 
the home cage. 
The first experiment examined the effect of systemic administration of the dopamine 
D1 antagonist SCH-23390 on the expression of conditioned morphine-induced immune 
alterations.  All animals received two conditioning sessions separated by 48 hours, during 
which an injection of morphine was paired with a distinctive environment, the conditioning 
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chamber.  Thus, the injection of morphine served as the unconditioned stimulus (US), and the 
distinctive environment served as the conditioned stimulus (CS).  During each session, rats 
were administered morphine immediately prior to being placed into the conditioning 
chambers for 1 hour.  Animals were returned to their home cages following each 
conditioning session.  This training phase was separated from the test day by a 12-day 
recovery period during which the animals received only handling.  On the test day, rats were 
assigned to one of three groups (n = 8) in which they were administered saline or SCH-23390 
(0.05, or 0.5 mg/kg, s.c.).  Thirty minutes following SCH-23390 administration, half of the 
animals in each group were re-exposed to the CS and the other half remained in the home 
cage.  Thus, there were six treatment groups (n = 4) in this experiment.  A previous study 
using extensive control manipulations showed that the immune alterations observed 
following exposure to the conditioning chamber are the result of conditioning processes 
(Coussons et al., 1992).  Immediately following the test session (one hour after the onset of 
CS re-exposure) animals were sacrificed by cervical dislocation and spleens were collected 
for immunological assessment.  Animals that remained in the home cages on the test day 
were sacrificed concurrently with those that were exposed to the CS.  
 The second experiment examined the effect of SCH-23390 administration into the 
nucleus accumbens shell prior to CS re-exposure on the conditioned immunomodulatory 
effects of morphine.  The conditioning procedures were identical to those described in the 
first experiment.  On the test day, rats received a microinjection of saline or SCH-23390 
(0.15 µg/side) into the nucleus accumbens shell.  Thirty minutes following microinjection, 
animals were either re-exposed to the conditioning chamber or remained in the home cage.  
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One hour later, animals were sacrificed to assess immune status.  This experiment was 
replicated, yielding an experimental design consisting of four groups (n = 10 per group). 
A third experiment was performed to control for the possibility that the effect of 
SCH-23390 was due to diffusion of the drug into other dopamine terminal regions near the 
injection site.  In this experiment, the effect of bilateral SCH-23390 administration into the 
nucleus accumbens core was assessed using the same procedures as described above.  
Animals were assigned to one of four groups (n = 5) in which they received saline or SCH-
23390 (0.15 µg/side) into the nucleus accumbens core. Thirty minutes following 
microinjection, animals were either re-exposed to the conditioning chamber or remained in 
the home cage.  One hour later, animals were sacrificed to assess immune status. 
In the fourth experiment, the effect of subcutaneous injections of the NPY Y1 
antagonist BIBP3226 was examined.  Rats received two conditioning sessions and 
subsequent re-exposure to the CS exactly as described in the procedures of the first 
experiment, but in this study animals received a subcutaneous injection of vehicle or 
BIBP3226 (0.1 or 1.0 mg/kg) on the test day.  Thirty minutes following injection, half of the 
animals in each dose group were re-exposed to the CS and the other half remained in the 
home cages.  Animals were sacrificed one hour later.  This experiment was replicated, giving 
an experimental design comprised of six treatment groups (n = 4 – 6 per group). 
 
Surgical and Microinjection Procedures 
For the intra-accumbens microinjections, stereotaxic surgeries were performed under 
anesthesia induced with a 0.2 ml intramuscular injection of a 1:1 (vol/vol) mixture of 
ketamine (100 mg/ml) and xylazine (20 mg/ml).  Animals were implanted with bilateral 26-
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gauge guide cannulae (Plastics One, Roanoke, VA) directed toward the nucleus accumbens 
shell (AP +1.7, ML ±0.8, DV –5.4) or the nucleus accumbens core (AP +1.7, ML ±1.5, DV –
4.8).  Coordinates are expressed as millimeters from bregma (Paxinos and Watson, 1986).  
Animals were given a one-week recovery period prior to the start of the conditioning trials.  
On the testing day, animals received a bilateral injection of saline or SCH-23390 (0.15 µg/ 
side).  SCH-23390 was administered in a 0.5 µl volume per side via a 33-gauge injector that 
protruded 2 mm beyond the tip of the guide cannula (final coordinates: AP +1.7, ML ±0.8, 
DV –7.4 for the shell; or AP +1.7, ML ±1.5, DV –6.8 for the core).  Intracranial drug 
microinjections were performed over a 30s  period using a microsyringe pump (Harvard 
Apparatus, Holliston, MA) and the injector was left in place for one minute to allow 
diffusion of the drug away from the injection site.  Immediately following the injection, 
animals were either returned to the home cage or re-exposed to the CS, depending on the 
treatment group.  Alcian blue dye was injected via the cannula following sacrifice, and brains 
were removed and post-fixed in 4% paraformaldehyde.  Brains were transferred to a 30% 
sucrose solution for cryoprotection, frozen, and stored at -80˚C for subsequent analysis.  
Accurate cannulae placements were verified by examination of unstained 50 µm tissue 
sections under a dissecting microscope.  Only animals with placements within the targeted 
region were included in the analysis. 
 
Tissue Collection 
 Following sacrifice, spleens were removed and prepared as a single-cell suspension as 
described in Chapter 2.  Splenic leukocytes were counted using a Hemavet 850 cell analyzer 
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(CDC Technologies Inc., Oxford, CT), and cell suspensions were adjusted to 5 × 106 
leukocytes/ml. 
 
Natural Killer Cell Assay 
 Splenic NK cell activity was assessed using a standard chromium release assay.  A 
detailed description of the assay is provided in Chapter 2. 
 
Splenocyte Proliferation Assay 
Splenocyte proliferative responses were assessed using mitogen stimulation assays.  
A detailed description of the assay is provided in Chapter 2. 
 
Statistics 
Data analysis for each experiment was performed using two-way analysis of variance 
(ANOVA) to assess the impact of drug antagonist treatment on conditioned immune 
alterations.  For the two-way analysis, the first factor was drug dosage and the second factor 
was the type of treatment on the test day, (i.e., re-exposure to the CS or home cage).  
Experimental replication was entered into the model as a covariate to control for inter-assay 
variability in the measured parameters for both the second and fourth experiments.  For all 
data sets, planned contrasts were performed in accordance with a priori hypotheses that 
SCH-23390 and BIBP3226 would antagonize the effect of the CS.  Planned contrasts in each 
analysis consisted of pairwise comparisons of means between CS re-exposed groups and 
home cage groups at each level of the factor “drug dosage.”  All analyses were performed 
with the alpha-level of significance set at p < 0.05 
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Results 
Systemic D1 Receptor Antagonism 
The first study examined the effect of systemic SCH-23390 administration on 
alterations of immune status induced by exposure to a distinctive environment (the CS) that 
had been previously paired with morphine administration.  The results of the NK cell assay 
are shown in Figure 4.1.  One animal was excluded from this analysis due to technical 
difficulties.  Analysis of variance revealed a significant main effect of CS re-exposure [F(1, 
17) = 26.89; p < 0.001], indicating that exposure to the CS suppressed NK activity.  More 
importantly, the analysis revealed a significant interaction between SCH-23390 dosage and 
CS re-exposure [F(2, 17) = 12.54; p < 0.001], indicating that the reduction in NK activity 
elicited by CS re-exposure was attenuated by SCH-23390 treatment.  Planned contrasts 
 
 
 
Figure 4.1  Effect of systemic dopamine D1 receptor antagonism on conditioned suppression 
of splenic NK cell activity.  Subcutaneous administration of SCH-23390 at a dose of 0.5 
mg/kg reversed the inhibition of splenic NK activity induced by CS re-exposure.  Data are 
expressed as lytic units (mean ± S.E.).  Solid bars indicate rats that remained in their home 
cages on the test day and open bars represent groups re-exposed to the CS on the test day.  *p 
< 0.01; **p < 0.001 compared with the home cage group that received the same dose of 
SCH-23390. 
 81
indicated that the CS re-exposed group differed from the corresponding home cage control 
group in animals that received saline (p < 0.01) or 0.05 mg/kg of SCH-23390 (p < 0.0001).  
However, at the high dose of SCH-23390 (0.5 mg/kg), planned comparisons showed that 
there was no difference between the groups exposed to the CS or the home cage on the test 
day, indicating that this dose of SCH-23390 fully blocked the conditioned suppression of NK 
activity. 
Figure 4.2 shows the results of the mitogen stimulation assays from the first 
experiment.  Re-exposure to the CS produced a significant decrease in splenocyte 
proliferation induced by Con-A (left panel) as revealed by a significant main effect of CS re-
exposure [F(1, 18) = 54.23; p < 0.0001].  Splenocyte proliferative responses to LPS (Figure 
4.2, right panel) were also significantly reduced in animals re-exposed to the CS as indicated 
by a significant main effect of CS re-exposure [F(1, 18) = 45.14; p < 0.0001].   There was no 
main effect of SCH-23390 dosage on the proliferative responses to Con-A [F(1, 18) = 2.71; p 
> 0.05] or LPS [F(1, 18) = 0.73; p > 0.05], nor was there a significant interaction between 
SCH-23390 dosage and CS re-exposure in either analysis (Fs ≤ 1.01).  Furthermore, SCH-
23390 administration did not antagonize the effect of CS re-exposure on responses to Con-A 
or LPS at any dose tested, as planned comparisons indicated that all groups re-exposed to the 
conditioning chamber on the test day displayed significantly lower proliferation compared to 
the corresponding home cage group (ps < 0.01). 
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Figure 4.2  Effect of systemic D1 receptor antagonism on conditioned suppression of 
lymphocyte proliferation.  Subcutaneous SCH-23390 administration did not attenuate the 
inhibitory effect of CS re-exposure on splenocyte mitogenic responses to Con-A (5.0 µg/ml) 
or LPS (5.0 µg/ml).  Data are expressed as disintegrations per minute (mean ± S.E.).  Solid 
bars indicate rats that remained in their home cages on the test day and open bars represent 
groups re-exposed to the CS on the test day.  *p < 0.01; **p < 0.001 compared with the home 
cage group that received the same dose of SCH-23390. 
 
 
 
 
Nucleus Accumbens D1 Receptor Antagonism 
The second experiment was conducted to investigate the effect of bilateral SCH-23390 
microinjections into the nucleus accumbens shell on the conditioned suppression of NK cell 
activity.  The results of the NK cell activity assay displayed in Figure 4.3 show that re-
exposure to the CS elicited a significant reduction in NK activity compared to animals that 
remained in the home cage on the test day, as evidenced by a significant main effect of CS 
re-exposure [F(1, 32) = 18.34; p < 0.001].  Analysis of variance further revealed a significant 
interaction between SCH-23390 administration and CS re-exposure [F(1, 32) = 4.92; p < 
0.05], indicating that the conditioned suppression of NK activity was attenuated by intra- 
accumbens SCH-23390 injections.  Planned contrasts indicated that the CS re-exposed group 
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differed from the corresponding home cage control group in animals that received saline (p < 
0.001).  However, in rats that received SCH-23390 microinjections, planned comparisons 
showed that there was no difference between the groups exposed to the CS or the home cage 
on the test day (p >.05).  These findings show that bilateral administration of SCH-23390 at a 
dose of 0.15 µg/0.5 µl is sufficient to fully antagonize the conditioned suppression of splenic 
NK activity. 
 
 
 
Figure 4.3  Effect of D1 receptor antagonism in the nucleus accumbens shell (A) or core (B) 
on conditioned suppression of NK cell activity.  A, Bilateral injections of SCH-23390 into 
the nucleus accumbens shell blocked the inhibitory effect of CS re-exposure on NK activity.  
B, Administration of SCH-23390 into the nucleus accumbens core did not prevent the effect 
of CS re-exposure.  Solid bars indicate rats that remained in their home cages on the test day 
and open bars represent groups re-exposed to the CS on the test day.  Data are expressed as 
lytic units (mean ± S.E.).  *p < 0.01; **p < 0.001 compared with the home cage group that 
received the same dose of SCH-23390.  
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NPY Y1 Receptor Antagonism 
Figure 4.4 displays the effect of subcutaneous BIBP3226 administration on the 
conditioned suppression of NK activity.  There was a significant main effect of CS re-
exposure [F(1, 22) = 19.04; p < 0.001], indicating that re-exposure to the CS reduced NK 
cytolytic activity.  The suppressive effect of CS re-exposure was attenuated by BIBP3226 
treatment, as determined by a significant interaction between CS re-exposure and BIBP3226 
dosage [F(2, 22) = 4.01; p < 0.05].  Planned comparisons indicated that the CS re-exposed 
group differed from the corresponding home cage group in animals that received saline (p < 
0.001) or 0.1 mg/kg of BIBP3226 (p < 0.05).  However, in animals that received the high 
dose of BIBP3226 (1.0 mg/kg), planned contrasts showed that there was no difference 
between the home cage and CS re-exposed groups (p > 0.05).  These findings indicate that 
the 1.0 mg/kg dose of BIBP3226 fully prevents the reduction in NK activity induced by re-
exposure to the CS. 
 
 
 
 
 
 
 
Figure 4.4  Effect of NPY Y1 receptor antagonism on conditioned reductions of NK cell 
activity.  Subcutaneous administration of BIBP3226 at a dose of 1.0 mg/kg blocked the 
inhibition of splenic NK activity induced by CS re-exposure.  Solid bars indicate rats that 
remained in their home cages on the test day and open bars represent groups re-exposed to 
the CS on the test day.  *p < 0.05; **p < 0.001 compared with the home cage group that 
received the same dose of BIBP3226. 
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Discussion 
Exposure to environmental stimuli previously paired with morphine induces 
conditioned immune alterations that mimic morphine’s pharmacological effects.  The present 
study shows that the conditioned suppression of NK activity is blocked by systemic 
administration of the D1 antagonist SCH-23390 prior to CS re-exposure, suggesting that 
morphine conditioned stimuli modulate NK activity through increased D1 receptor-mediated 
signaling.  In contrast, SCH-23390 did not attenuate the conditioned suppression of 
splenocyte proliferative responses to Con-A or LPS.  This finding is notable because it shows 
that the learned association between morphine and the CS is not disrupted by D1 antagonist 
treatment and furthermore indicates that neuroimmune efferent communication is not 
impaired in a nonspecific manner.  Moreover, the selective role of D1 receptors in mediating 
conditioned effects on NK activity mirrors our previous findings with morphine 
administration in which SCH-23390 was shown to block the effect of morphine on NK 
activity (Saurer et al., 2006a) but not lymphocyte proliferation (unpublished observations).   
The current findings further demonstrate that microinjection of SCH-23390 into the 
nucleus accumbens shell prior to CS re-exposure completely blocks the suppression of NK 
activity.  Thus, these data indicate that the activation of D1 receptors in the nucleus 
accumbens is necessary for the expression of conditioned reductions in splenic NK cell 
activity.  Because increased dopamine transmission in the nucleus accumbens shell has been 
widely implicated in the acquisition of associative (Pavlovian) learning (Di Chiara et al., 
2004; Pezze and Feldon, 2004), an important issue for future investigations to address is 
whether the nucleus accumbens also plays a role in the development of associative learning 
processes which establish conditioned effects on immunity.  One of the major advantages of 
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the Pavlovian conditioning model is that it permits the separation of afferent and associative 
processes from efferent control mechanisms. For example, although β-adrenoceptor 
antagonists block the expression (recall) of conditioned effects on mitogen-induced 
lymphocyte proliferation, they do not affect the conditioned response if administered during 
acquisition, indicating that β-adrenoceptor activity is not required for the development of the 
conditioned response (Coussons-Read et al., 1994b; Lysle et al., 1991).  Since blocking the 
unconditioned response does not impair the UCS-CS associative processes that establish the 
conditioned response, the interpretation is that increased catecholamine release (and the 
subsequent activation of β-adrenoceptors) represents the efferent phase of the unconditioned 
response.  Whether the blockade of D1 receptors in the nucleus accumbens shell during 
acquisition disrupts conditioned effects on the immune system is presently unknown.  If for 
example, such manipulations did not influence conditioned responses, these results would 
indicate that D1 activation is intimately involved in efferent neuroimmune signaling, but not 
in associative learning per se.  Based on the established role of the nucleus accumbens in 
learning processes, an important avenue for future investigations will be to evaluate the role 
of D1 receptor during the acquisition of UCS-CS associations responsible for conditioned 
immune alterations. 
Although further studies are necessary to elucidate the role of the nucleus accumbens 
in the conditioning of immunity, the involvement of the accumbens may simply represent a 
more fundamental efferent neuroimmunoregulatory mechanism, as morphine’s 
pharmacological effects on NK activity are also abrogated by blocking the activation of D1 
receptors in the nucleus accumbens shell.  The precise neuroimmune pathway through which 
accumbens D1 receptors activation causes an inhibition of splenic NK cell activity is not fully 
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understood, but converging evidence suggests that it may involve the modulation of efferent 
sympathetic nerve outflow.  For instance, neural control of splenic NK cell activity is a well 
documented phenomenon which occurs primarily via the sympathetic nervous system (Irwin 
et al., 1990; Katafuchi et al., 1993a), and the nucleus accumbens shell has known efferent 
projections to hypothalamic autonomic regulatory centers (Heimer et al., 1991; Usuda et al., 
1998).  Moreover, several hypothalamic nuclei have been shown to modulate splenic NK 
activity including those which receive direct afferent projections from the nucleus accumbens 
shell (Katafuchi et al., 1993a; Wenner et al., 1996; Wrona and Trojniar, 2003; Wrona and 
Trojniar, 2005).  Thus, one possibility is that dopamine transmission in the nucleus 
accumbens modulates sympathetic outflow, thereby suppressing NK activity. 
There is accumulating evidence that the conditioned effects of morphine on immune 
status are mediated by neural processes similar to those which underlie the drug’s 
pharmacological effects.  This is not entirely surprising, considering that both conditioned 
and unconditioned effects are mediated through opioid receptors (Coussons-Read et al., 
1994a; Fecho et al., 1996a).  The imperative distinction however, is that conditioned immune 
alterations are produced by endogenous opioids, as no drug is actually administered on the 
test day.  Thus, conditioned effects on immunity reflect the inherent capacity of the brain to 
modify immune functions.  Given the ability of endogenous opioids to modulate immune 
status, it is no coincidence that stimuli which induce the release of opioids, such as aversive 
or stressful stimuli, produce similar opioid-dependent immunological alterations which can 
also be conditioned to environmental stimuli (Lysle et al., 1992a; Perez and Lysle, 1997; 
Shavit et al., 1984).  The essential mechanistic feature shared by unconditioned and 
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conditioned effects of both aversive stimuli and opioid drugs is the requisite activation of 
opioid receptors—specifically µ-opioid receptors. 
The present findings provide additional support for the hypothesis that morphine’s 
conditioned and unconditioned effects are mediated by similar mechanisms.   The inhibitory 
effects of morphine on splenic T and B cell proliferative responses are mediated through β-
adrenoceptors specifically, whereas NPY Y1 receptors mediate morphine’s effect on NK cell 
activity (Fecho et al., 1993a; Saurer et al., 2006b).  In the present study, we show that the Y1 
antagonist BIBP3226 blocks the conditioned suppression of NK cell activity, indicating that 
Y1 receptors also mediate CS-induced effects on NK activity.  Because BIBP3226 reportedly 
does not penetrate the blood-brain barrier when administered systemically, these findings 
implicate the involvement of peripheral Y1 receptors specifically (Doods et al., 1996).  Given 
the results of prior studies which indicate that NPY Y1 receptors mediate the dopamine-
dependent effects of morphine on immune status, the current findings suggest that 
conditioned increases in nucleus accumbens D1 receptor activation lead to the suppression of 
splenic NK activity by facilitating the release of NPY from sympathetic nerves.  NPY may in 
turn, directly interact with NK cells to inhibit cytolysis, as splenic lymphocytes express 
functional Y1 receptors (Bedoui et al., 2002; Petitto et al., 1994) and NPY produces direct 
and dose-dependent suppressive effects on NK activity in vitro (Nair et al., 1993). 
The involvement of NPY provides further evidence for the role of the sympathetic 
nervous system in conditioned immune alterations.  Although early theories suggested that 
conditioned immunomodulation was simply a nonspecific stress reaction involving activation 
of the hypothalamic-pituitary-adrenal axis and the release of adrenocortical steroids, this 
explanation does not adequately account for many, if not most, conditioned effects on the 
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immune system (e.g., Ader et al., 1979; Roudebush and Bryant, 1991).  For example, the 
conditioned immunosuppressive effects of cyclosporine A on T-cell proliferation and 
cytokine production have been shown to be mediated solely via the sympathetic innervation 
of the spleen (Exton et al., 1998).  Additionally, prior studies from our laboratory have 
shown that peripheral β-adrenoceptor activity mediates the conditioned effects of both 
aversive stimuli and morphine on the immune system (Coussons-Read et al., 1994b; Luecken 
and Lysle, 1992).  Thus, the sympathetic nervous system may represent the principal 
neuroimmune pathway through which a variety of conditioned stimuli induce immune 
alterations, as sympathetic efferent mechanisms have been established in several paradigms.   
In conclusion, the present study demonstrates that the expression of morphine’s 
conditioned effects on splenic NK cell activity requires the activation of dopamine D1 
receptors in the nucleus accumbens.  Furthermore, the current results show that antagonism 
of NPY Y1 receptors with BIBP3226 also prevents the conditioned suppression of NK 
activity.  Taken together with the results of previous investigations, the present findings 
provide additional support for the hypothesis that the conditioned and unconditioned defects 
of morphine involve the same neural pathways by demonstrating the involvement of similar 
dopamine and NPY receptor mechanisms.  In addition, the present data suggest that 
conditioned increases in the activation of nucleus accumbens D1 receptors may induce 
reductions in splenic NK activity by stimulating the release of NPY.  These findings add to 
our current knowledge regarding the neural mechanisms responsible for conditioned 
modulation of immunity by providing the first demonstration for the role of the nucleus 
accumbens in Pavlovian conditioned immunomodulation.  
 
 
 
 
 
CHAPTER 5 
 
GENERAL DISCUSSION 
 
 
 
 
Experimental Findings 
 Collectively, the studies comprising the current dissertation provide important new 
data regarding the neurobiological mechanisms of opioid-induced immune alterations.  The 
investigation of interactions between opioids and neurotransmitter systems has led to 
significant advancements in our present understanding of how opioids produce analgesia and 
why opioid drugs are highly addictive.  However, a similar research approach has not yet 
been widely exploited to ascertain how opioid drugs modulate immune function.  The present 
dissertation has drawn upon existing data concerning interactions between opioids and 
central dopamine systems to evaluate the role of the nucleus accumbens dopamine in opioid-
induced immunomodulation. 
The findings of Chapter 2 reveal that the nucleus accumbens shell is an essential 
neural substrate underlying the effects of opioids on immunity.  Those studies showed that 
the stimulation of dopamine D1 receptors in the nucleus accumbens shell is necessary for 
opioid-induced suppression of splenic NK cell activity.  Moreover, in the absence of opioid 
administration, the stimulation of D1 receptors alone produced comparable reductions in NK 
activity, supporting a fundamental role of the nucleus accumbens in neuroimmune regulation.  
Additional experiments further demonstrated that heroin’s widespread inhibitory effects on 
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LPS-induced iNOS expression in peripheral tissues also require the activation of D1 receptors 
in the nucleus accumbens. 
Chapter 3 explored potential efferent pathways involved in opioid-induced immune 
alterations by investigating the role of NPY as a peripheral determinant of the central effects 
of opioids.  The results of these studies showed that peripheral NPY Y1 receptors mediate 
opioid-induced immunosuppressive effects on splenic NK activity, as well as the production 
of iNOS in response to LPS challenge.  Because NPY Y1 receptor antagonism selectively 
blocked opioid effects on immune parameters previously shown to be dependent on nucleus 
accumbens dopamine, these findings suggest that NPY mediates the dopamine-dependent 
immunomodulatory effects.  Moreover, opioid-induced reductions in the mitogenic responses 
of T-cells and B-cells—immune responses that are modulated independently of accumbens 
D1 receptor stimulation, as shown in Chapter 2—were not influenced by NPY Y1 receptor 
antagonist manipulations.  Taken together, the studies of Chapter 3 provide convincing 
evidence that the sympathetic peptide transmitter NPY is an important peripheral mediator of 
the dopamine-dependent immunomodulatory effects of opioids. 
Whereas Chapters 2 and 3 revealed novel mechanisms whereby opioids produce 
pharmacological effects on the immune system, Chapter 4 demonstrated that similar neural 
pathways underlie the conditioned effects of opioids.  These studies showed that re-exposure 
to environmental stimuli previously paired with morphine produced conditioned reductions 
in NK cell activity that were mediated through D1 receptors in the nucleus accumbens shell.  
Furthermore, the conditioned effects on NK activity were likewise prevented by blocking 
NPY Y1 receptors prior to CS re-exposure.  Remarkably, these findings suggest that stimuli 
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associated with the opioids are capable of inducing immune alterations by engaging the same 
neural mechanisms responsible for the pharmacological effects of opioid drugs. 
 
Potential Mechanisms 
Opioid/Dopamine Interactions  
Collectively, the present studies highlight the role of the nucleus accumbens shell as a 
neural substrate of opioid-induced immune alterations.  These studies show that stimulation 
of dopamine D1 receptors in particular, is necessary for the expression of opioid effects on ex 
vivo and in vivo immune responses.  Although the brain mechanisms that regulate 
immunological functions are only beginning to be understood, these findings provide 
important clues regarding the neural circuitry involved in immunomodulation. 
The periaqueductal gray matter (PAG) has been identified as a site of morphine’s µ-
opioid receptor interactions responsible for the suppression of NK cell activity (Lysle et al., 
1996; Weber and Pert, 1989).  In light of the present findings, the relationship between the 
PAG and the nucleus accumbens is of significant interest.  It is currently believed that 
morphine primarily increases extracellular dopamine in the nucleus accumbens by 
suppressing the tonic inhibitory influence of GABA interneurons on dopamine neurons that 
emanate from the ventral tegmental area (VTA) (Johnson and North, 1992; Klitenick et al., 
1992).  However, given that morphine has been shown to suppress NK activity via µ-opioid 
receptors in the PAG, the role of VTA µ-opioid receptors is unclear.  Similar to its actions in 
the VTA, morphine is also believed to increase the activity of PAG efferents by suppressing 
the tonic influence of inhibitory GABA interneurons (Renno et al., 1992; Stiller et al., 1996).  
One possibility is that a direct dopaminergic projection from the PAG to the accumbens is 
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involved in morphine’s suppressive effect on NK activity, as there is evidence that dopamine 
neurons project from the PAG to the nucleus accumbens shell (Hasue and Shammah-
Lagnado, 2002).  The significance of this pathway is uncertain however, since the majority of 
the dopaminergic input to the nucleus accumbens appears to originate from the VTA (Hasue 
and Shammah-Lagnado, 2002). 
An alternative hypothesis is that opioid receptors in multiple sites are capable of 
modulating immune status.  It is possible that the stimulation of µ-receptors in the VTA or 
the nucleus accumbens inhibit immune parameters in addition to PAG stimulation as part of a 
complex circuitry involved in neuroimmune regulation.  Studies performed in rabbits have 
shown that microinjection of morphine into the nucleus accumbens induces the release of 
endogenous opioids in the PAG, whereas morphine injection into the PAG induces opioid 
peptide release in the nucleus accumbens (Ma et al., 1992; Ma and Han, 1992).  Furthermore, 
naloxone administration into either the PAG or the nucleus accumbens prevents the analgesic 
effect of morphine microinjection into the other structure (Ma and Han, 1991).  Thus, it 
appears that opioid activities in the nucleus accumbens and PAG are connected through an 
interrelated positive feedback system.  Interestingly, both reinforcing and analgesic effects of 
morphine can be elicited by injecting morphine into the PAG, the VTA, or the nucleus 
accumbens (Corrigall and Vaccarino, 1988; Devine and Wise, 1994; Manning et al., 1994; 
Olmstead and Franklin, 1997).  It is likely that opioid-induced immune alterations similarly 
involve interactions between multiple brain nuclei as part of a complex circuitry involved in 
neuroimmune modulation.  An exciting issue for future studies will be to determine whether 
the stimulation of µ-opioid receptors in the nucleus accumbens and VTA also produce 
reductions in NK activity and iNOS production. 
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Nucleus Accumbens Efferent Pathways 
Another important issue raised by the current studies concerns the output pathway 
through which dopamine receptor activity in the nucleus accumbens translates into peripheral 
immune alterations.  Because the current findings suggest that dopamine-dependent immune 
alterations are mediated peripherally via NPY Y1 receptors, this pathway appears to involve 
the sympathetic nervous system.  However, precisely how the nucleus accumbens modulates 
sympathetic outflow in the context of immunomodulation has not been clearly delineated.  
While little is known about the central mechanisms that modulate iNOS expression in 
peripheral tissues, neural control of splenic NK cell activity is a well documented 
phenomenon which is mediated primarily by the sympathetic nervous system via tonic 
inhibition from the splenic nerve (Irwin et al., 1990; Katafuchi et al., 1993a).  The activity of 
the splenic nerve, which releases norepinephrine and NPY, appears to be under the central 
control of the hypothalamus (Katafuchi et al., 1993b; Take et al., 1995).  The nucleus 
accumbens shell has direct connections to several hypothalamic autonomic regulatory centers 
(Heimer et al., 1991; Usuda et al., 1998), suggesting that this may be one pathway involved 
in the effects of opioids.  Moreover, several hypothalamic nuclei have been shown to 
modulate splenic NK activity including the lateral hypothalamus, which receives extensive 
afferent input from the nucleus accumbens shell (Okamoto et al., 1996; Wenner et al., 1996; 
Wrona and Trojniar, 2003; Wrona and Trojniar, 2005).  Thus, one possibility is that 
dopamine transmission in the nucleus accumbens shell alters splenic NK activity through 
interactions with hypothalamic nuclei that modulate the activity of the sympathetic 
innervation to peripheral tissues. 
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NPY Mechanisms 
The sympathetic nervous system modulates immunocyte functions via direct 
innervation of target tissues or by inducing the release of signaling molecules into the 
systemic circulation via the adrenal medulla.  Some evidence indicates that the sympatho-
adreno-medullary pathway mediates a subset of opioid-induced effects.  For instance opioid, 
effects on splenocyte mitogenic responses are abrogated by β-adrenoceptor blockers and by 
adrenalectomy, suggesting that these effects are involve the release of catecholamines from 
the adrenal medulla (Fecho et al., 1993a; Fecho et al., 1996b).  However, adrenalectomy does 
not prevent all opioid induced effects, such as the suppression of NK cell activity, so it is 
unlikely that the adrenals are the source of NPY that mediates the effects observed in the 
present studies.  Moreover, other studies have found that removal of the adrenals does not 
attenuate the increase of plasma NPY levels in response to stress (Mormede et al., 1990).  A 
more plausible explanation is that the effects on splenic NK cell activity and iNOS 
production observed in the present studies are mediated directly through sympathetic 
innervation of target tissues.  As discussed in Chapter 3, sympathetic fibers innervating the 
spleen provide a “hard-wired” connection between the nervous system and immune cells.  
Moreover, sympathetic nerves also supply the lung and liver—an important observation 
considering heroin’s effects on iNOS expression in these tissues.  Thus, the local release of 
NPY in target tissues by sympathetic nerves may modulate NK activity and iNOS 
production. 
NPY can potentially influence immune measures at the cellular level through a 
number of pathways, as it has pleiotropic effects on immunocyte physiology including the 
modulation of leukocyte mobilization (Bedoui et al., 2002), cytokine expression (Bedoui et 
 96
al., 2003; Straub et al., 2000b), monocyte chemotaxis (Straub et al., 2000a), and antibody 
production (Friedman et al., 1995).  With respect to NK cell activity it appears that NPY acts 
directly via NK cell-expressed Y1 receptors to inhibit cytolytic activity, as functional NPY Y1 
receptors have been cloned from rat lymphocytes (Petitto et al., 1994) and in vitro studies 
indicate that NPY induces a direct and dose-dependent inhibition of NK cell activity (Nair et 
al., 1993).  However, there is less certainty regarding the effects of NPY on iNOS expression.  
Because NPY has widespread effects on immune parameters, it is possible that Y1 receptors 
indirectly modulate iNOS production via leukocyte mobilization or by altering the 
production of cytokines that induce iNOS.   The most parsimonious explanation however, is 
that the NPY acts directly via Y1 receptors on iNOS producing cell types such as the 
macrophage.  NPY Y1 receptors have been shown to modulate macrophage functions in vitro 
(Dimitrijevic et al., 2005), and macrophages appear to be the major site of iNOS expression 
in LPS-treated rats (Buttery et al., 1994; Cook et al., 1994).  Thus, Y1 receptors expressed by 
NK cells and macrophages may directly underlie the inhibitory effects of opioids on cytolytic 
activity and iNOS production, respectively.   
The observation that the proposed dopamine/NPY pathway mediates a subset of 
opioid-induced effects (i.e., NK activity and iNOS production) raises important questions 
about the relationship between these immune measures.  Although it appears that NK activity 
and iNOS production are two distinct parameters modulated in a similar manner by the 
nervous system, another possibility is that these two measures reflect the same underlying 
immunological perturbation.  In addition to macrophages, other cell types such as NK cells 
are capable of generating iNOS and producing nitric oxide (Bandaletova et al., 1993; Cifone 
et al., 1999; Salvucci et al., 1998).  Thus, reduced iNOS expression in NK cells, for example, 
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could potentially contribute to heroin’s effects.  Even so, it is unlikely that effects on NK 
cell-derived iNOS could fully account for the effects of heroin observed in the current studies 
since the production of large quantities of iNOS in response to LPS is largely attributable to 
macrophage cell types. 
Because NK cells are capable of nitric oxide production, another interesting 
possibility is that Y1 receptor activation inhibits NK cytotoxic activity by suppressing iNOS 
production.  NK cell-mediating killing is primarily believed to involve the release of 
cytotoxic granules (e.g., perforin and granzyme) or the activation of cell membrane death 
receptors (e.g., Fas) (for review see Russell and Ley, 2002), but recent evidence indicates 
that the induction of iNOS is also involved in NK cell cytotoxic activity (Cifone et al., 1999; 
Filep et al., 1996; Jyothi and Khar, 1999).  While it is well known that nitric oxide can induce 
apoptosis directly, it is presently unclear if NK cell-derived nitric oxide performs a similar 
function or simply modulates other cytotoxic pathways.  In any case, Y1 receptors are clearly 
important in NK cell cytotoxic activity. Whether the intracellular mechanism involves 
modulating iNOS production will need to be addressed by future studies. 
   
Biological Implications 
These studies are the first to show that the modulation of nucleus accumbens 
dopamine is directly involved in the effects of opioids on immune physiology.   Researchers 
in the field of drug addiction have long appreciated that the reinforcing effects of addictive 
drugs are intimately related to the activation of dopamine neurons projecting from the ventral 
tegmental area (VTA) to the nucleus accumbens.  Because the present findings show that 
stimulation of D1 receptors in the shell of the nucleus accumbens activates central circuits 
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that modulate peripheral immune responses, a major implication is that addictive drugs may 
produce immunological perturbations through common pathways.  Although few studies 
have systematically examined the immunological consequences of different classes of drugs 
under the same experimental parameters, virtually every addictive drug produces detrimental 
effects on facets of the immune response.  In particular, reductions in splenic NK cell activity 
have been reported following in vivo administration of alcohol (Boyadjieva et al., 2001; Wu 
and Pruett, 1996a), cannabinoids (Massi et al., 2000; Patrini et al., 1997), amphetamine 
(Nunez-Iglesias et al., 1996), and cocaine (Pacifici et al., 2003).  Although it is unknown 
whether nucleus accumbens D1 receptor mechanisms contributed to the observed NK 
suppression in these studies, the notion that different classes of abused drugs modulate 
immunity by acting through a common central mechanism is an intriguing hypothesis worthy 
of further investigation.  
 Another major implication of the present findings is that the same neural processes 
responsible for morphine’s pharmacological effects may mediate the conditioned effects of 
the drug on immune status.  Since conditioned effects on immunity reflect the inherent 
capacity of the brain to modify immune functions, the data further imply that the proposed 
dopamine/NPY pathway is a component of normal physiological regulatory mechanisms 
involved in modulating the immune response.  In particular, the current findings may be 
relevant to certain types of stress-induced immune alterations.  For example, it is known that 
both physical and psychological stressors produce immune alterations that are mediated by 
brain opioid receptors (Cunnick et al., 1988; Lysle et al., 1992a; Shavit et al., 1984).  
Interestingly, it appears that certain types of stress also increase the release of nucleus 
accumbens dopamine (Barrot et al., 1999; Kalivas and Duffy, 1995; Young et al., 1993).  
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Therefore, in addition to demonstrating neural mechanisms of immunomodulation produced 
by opioid drugs and drug-conditioned stimuli, the present findings may also have 
implications regarding the ability of stress and emotional processes to modify the immune 
response. 
The involvement of the nucleus accumbens shell in modulating immune responses 
raises important questions about the functions of nucleus accumbens dopamine.  Historically, 
the nucleus accumbens has been construed as a “limbic-motor interface” that integrates 
limbic inputs from the amygdala, hippocampus, and prefrontal cortex, and translates this 
information into behavioral action via outputs to autonomic and motor nuclei (Mogenson et 
al., 1980).  The proximate question as to what specific information is encoded by nucleus 
accumbens dopamine has generated a multitude of competing hypotheses.  These hypotheses, 
which are not necessarily mutually exclusive, have largely addressed the role of nucleus 
accumbens in learning and motivational processes as they relate to natural or drug rewards 
(e.g., Berridge and Robinson, 1998; Di Chiara, 2002; Koob and Le, 2005; Salamone and 
Correa, 2002; Wise, 2004).  However, because the nucleus accumbens has been implicated in 
modulating a diversity of physiological functions—including blood pressure (Sakata et al., 
2002), stress responses (Ikemoto and Goeders, 1998), wakefulness (Ponzoni et al., 1995), and 
immunity (Nistico et al., 1994)—a broader perspective is warranted to account for its 
participation in these more global functions.  Recently it has been postulated that 
dopaminergic projections to the nucleus accumbens are part of a set of coordinated neuronal 
mechanisms that enables organisms both to find biologically important stimuli from the 
environment as well as avoid or escape danger (Ikemoto, 2007; Ikemoto and Panksepp, 
1999).  This hypothesis states that nucleus accumbens dopamine plays a major role in 
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incentive learning and in the regulation of “action-arousal,” which is defined as a state of 
arousal that energizes organisms for interactions with the environment.  This explanation 
satisfactorily explains the role of the nucleus accumbens in neuroimmune modulation, 
because the concept of action-arousal encompasses reciprocal interactions between 
cognitive/psychological processes and behavioral/physiological responses.  Thus, increases 
in nucleus accumbens dopamine may serve to energize organisms for interactions with the 
environment in part, by producing an activation of the sympathetic nervous system and HPA 
axis.  Evidence to support this notion comes from studies showing that electrical stimulation 
of the VTA/medial forebrain bundle elicits increases of both plasma catecholamine and 
glucocorticoid levels (Burgess et al., 1993).  Importantly, increased states of physiological 
arousal also modulate nucleus accumbens dopamine in a reciprocal manner, as 
glucocorticoids and mild stressors have been shown to increase dopamine activity in the 
nucleus accumbens shell (Barrot et al., 1999; Barrot et al., 2000; Piazza et al., 1996).  
Immunomodulation thus, may be construed as a consequence of the heightened state of 
autonomic arousal that accompanies increased nucleus accumbens dopamine. 
 While increased arousal states may explain the link between nucleus accumbens 
dopamine and altered immune measures, existing theoretical frameworks do not address the 
ultimate “why” question as to the adaptive value of suppressed immune states.  To 
understand why immunosuppression may be adaptive under certain environmental contexts, 
it should be emphasized that the immune system and the nervous system do not operate 
autonomously, but rather communicate in a reciprocal manner.  Immune cells produce 
molecules and receptors for classically defined neurotransmitters, and the nervous system 
produces and molecules and receptors traditionally categorized as cytokines.  This point is 
 101
critical, because during states of infection, activated immune cells release proinflammatory 
cytokines (e.g., IL-1 and TNF-α) that act upon the brain to elicit a constellation of non-
specific infection symptoms collectively termed “sickness behaviors” (for review, see 
Dantzer and Kelley, 2007).  These symptoms include both fever and behavioral changes such 
as fatigue, exaggerated pain responses, anhedonia, listlessness, hypersomnia, reduced 
appetite, inability to concentrate, and loss of interest in sexual and social activities.  
Collectively, sickness behaviors have been conceptualized as the expression of a 
motivational state that enhances survival and promotes recovery from infection (Kelley et al., 
2003).  However, there are palpable negative consequences of sickness behaviors if the 
organism is in a temporal situation or environmental context that requires increased arousal, 
attention, energy expenditure, or vigilance; for example, during periods of increased 
predation risk, or during migratory or mating seasons. Thus, it may be adaptive in certain 
contexts to delay the onset of sickness behaviors produced by the immune response if the 
benefits (e.g., short-term survival, enhanced reproduction) exceed the costs (e.g., heightened 
risk of infectious disease). 
Perhaps not coincidentally, the motivational states modulated by nucleus accumbens 
dopamine diametrically oppose the motivational states that result from immune activation 
during sickness.  As discussed previously, nucleus accumbens dopamine is believed to play 
an important role in action-arousal states that enable the organism to interact with 
biologically significant stimuli.  In line with the adaptive value of heightened action-arousal 
states, increased nucleus accumbens dopamine in response to relevant environmental stimuli 
may function to limit the production of proinflammatory cytokines that could compromise 
the performance of adaptive behavioral responses.  In other words, suppression of the 
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immune response and the prolongation of sickness behaviors could serve to promote 
immediate survival or to enhance reproductive opportunities, thereby increasing the 
organism’s evolutionary fitness.  This proposed conceptual framework offers an evolutionary 
explanation for a number of empirically observed phenomenon, and it is consistent the fact 
that the nucleus accumbens integrates information from limbic structures about salient 
changes in the environment with respect to self-preservation and procreation (MacLean, 
1990).   
 
Conclusions 
Substantial evidence indicates that opioid use is associated with negative health 
consequences.  Given the widespread medical and recreational uses of opioid drugs, it is 
important to understand the effects of opioids on immunity and health, as well as the 
physiological mechanisms of those effects.  The present dissertation has proposed a novel 
neuroimmune pathway that underlies the effects of opioid drugs on imperative 
immunological functions. These findings show that the interaction of opioids with dopamine 
signaling in the nucleus accumbens shell is critically involved in modulating immune status.  
Furthermore, the present studies suggest that increased nucleus accumbens dopamine 
transmission modulates specific immune parameters by facilitating the release of NPY from 
sympathetic nerves.  Importantly, the dissertation shows that this pathway not only underlies 
the immunomodulatory effects of exogenous opioids, but also the effects of stimuli 
associated with opioid administration.  As the proposed pathway is involved in the effects of 
morphine, heroin, and conditioned stimuli on both functional and in vivo immune measures, 
these findings have significant implications for the mechanisms whereby opioids and 
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behavioral factors modulate the immune system.  Additionally, the proposed mechanisms 
may also have mechanistic implications for the immunomodulatory effects of other addictive 
drugs or stressful stimuli that activate mesoaccumbens dopamine neurons.  Collectively, 
these findings provide important insights into how the actions of opioids in the brain translate 
into peripheral immune alterations. 
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